Index

adherence, see compliance, 3

adjust/adjustment

adjusted mortality rate, 3
adjustment, 4
adjustment procedure, 4
direct rate adjustment, 72
indirect rate adjustment, 125
rate adjustment, 225
simultaneous adjustment, 252
stepwise adjustment, 259
treatment application and adjustment, 279
treatment application and adjustment followup visit, 279

age

age, 5
age of assent, 6
age of consent, 6
age of emancipation, 6
age of majority, 6
emancipated minor, 82
mature minor, 153
years of age, 305

agency and place index

Cochrane Central Register of Controlled Trials, 38
European Medicines Agency, 86
Food and Drug Administration (FDA), 100
National Center for Health Statistics (NCHS), 165
National Death Index (NDI), 165
National Institutes of Health (NIH), 165
National Technical Information Service (NTIS), 166
Office for Human Research Protections (OHRP), 178
Office of Research Integrity (ORI), 178
Office of Research on Women’s Health (ORWH), 178
Securities and Exchange Commission (SEC), 246
Society for Clinical Trials (SCT), 254
Teratology Society, 78
World Health Organization (WHO), 303
Aickin M, 157
allocation, see assignment, 6
Ambroz A, 223
Amplatz K, 76

analysis

ad hoc meta-analysis, 2
aggregate patient data meta-analysis, 6
analysis by administered treatment, 7
analysis by assigned treatment, 7
analysis by intention to treat, 7
analysis by level of treatment adherence, 7
analysis center, 7
analysis committee, 7
analysis data edit, 8
analysis database, 8
analysis dataset, 8
analysis of covariance (AnoCo), 8
analysis of variance (AnoVa), 8
analysis plan, 8
analysis principle, 8
analysis rule, 240
Bayesian analysis, 18
best-case analysis, 19
best–worst-case analysis, 19
bivariate analysis, 23
centralized data analysis, 30
cohort analysis, 39
confirmatory data analysis, 46
cost–benefit analysis, 58
cost–effectiveness analysis, 58
cost–utility analysis, 58
critical path analysis, 59
cross-sectional analysis, 59
cumulative meta-analysis, 60
designed meta-analysis, 70
destructive data analysis, 70
distributed data analysis, 73
efficacy analysis, 81
exploratory data analysis, 90
factor analysis, 94
final data analysis, 97
frequentist, 103
frequentist analysis, 103
futility analysis, 105
group sequential interim data analysis, 111
horseback analysis, 117
individual patient data meta-analysis, 126
inefficacy interim analysis, 126
intention to treat analysis, 129
interim data analysis, 130
lifetable analysis, 144
likelihoodist, 145
linear regression analysis, 145
masked data analysis, 152
meta-analysis, 156
multiple linear regression analysis, 162
multiple logistic regression analysis, 162
multivariate analysis, 163
muta-analysis, 163
path analysis, 188

317
analysis (Continued)
  per assignment analysis, 191
  per protocol analysis, 191
  primary analysis, 205
  primary data analysis, 206
  principal analysis, 207
  principal component analysis, 207
  quick and dirty analysis, 219
  real-time meta-analysis, 226
  regression analysis, 229
  risk factor analysis, 239
  risk profile analysis, 240
  risk–benefit analysis, 240
  safety analysis, 241
  secondary data analysis, 245
  sensitivity analysis, 247
  sequential data analysis, 247
  subgroup analysis, 267
  survival analysis, 269
  time series analysis, 277
  treatment effects monitoring and analysis committee, 282
  treatment-related analysis bias, 286
  two-way analysis of variance, 289
  valid analysis, 297
  worst-case analysis, 303
Anderson LK, 31
Antman EM, 101
application
  Abbreviated New Drug Application (ANDA), 1
  biological license application, 22
  Establishment License Application (ELA), 85
  Investigational Device Exemption Application (IDEA), 133
  Investigational New Drug Application (INDA), 133
  New Drug Application (NDA), 168
  Premarket Approval Application, 204
  product license application (PLA), 209
  request for application (RFA), 234
  research application, 235
  research grant application, 235
  treatment application and adjustment followup visit, 279
Armitage P, 129, 183
assent
  age of assent, 6
  assent, 10
  assent form, 11
  consent, see also, 48
  documented assent, 74
  oral assent, 181
  signed assent, 250
  verbal assent, 300
  witnessed assent, 303
  written assent, 304
assignment
  adaptive treatment assignment, 2
  alteration treatment assignment, 7
  assignment, 11
  balanced incomplete treatment assignment block design, 15
  baseline adaptive treatment assignment, 16
  bias free treatment assignment, 20
  biased coin treatment assignment, 20
  blocked treatment assignments, 25
  complete treatment assignment block, 43
  complete treatment assignment block design, 43
  controlled treatment assignment, 56
  envelope treatment assignment, 84
  equal treatment assignment, 85
  expected assignment ratio, 88
  fixed randomization design, 98
  fixed treatment assignment, 98
  fixed treatment assignment design, 98
  fixed treatment assignment ratio, 98
  fixed treatment assignment schedule, 98
  group treatment assignment, 111
  haphazard treatment assignment, 113
  imbalance minimization treatment assignment, 120
  incomplete treatment assignment block design, 123
  indirect treatment assignment system, 125
  masked treatment assignment, 45, 152
  minimum likelihood treatment assignment, 157
  nonmasked treatment assignment, 171
  nonuniform treatment assignment, 172
  observed treatment assignment ratio, 176
  odd–even method of treatment assignment, 176
  open treatment assignment, 180
  outcome adaptive random treatment assignment, 182
  outcome adaptive treatment assignment, 182
  per assignment analysis, 191
  play-the-winner treatment assignment, 198
  post-assignment consent, 201
  preassignment examination, 203
  preassignment visit, 203
  random assignment, 221
  random treatment assignment, 222
  randomization design, 223
  restricted treatment assignment schedule, 237
  simple treatment assignment, 251
  specified assignment ratio, 255
  stratified random treatment assignment, 261
  stratified treatment assignment, 261
  systematic treatment assignment, 271
  treatment assignment, 279
  treatment assignment bias, 280
  treatment assignment block, 280
  treatment assignment block effect, 280
  treatment assignment block size, 280
  treatment assignment design, 280
  treatment assignment probability, 280
  treatment assignment ratio, 280
  treatment assignment unit, 280
two-armed bandit outcome adaptive assignment, 288
uncontrolled treatment assignment, 292
uniform treatment assignment, 294
uniform treatment assignment ratio, 294
unmasked treatment assignment, 295
unrestricted random assignment, 295
unrestricted treatment assignment, 295
unrestricted treatment assignment schedule, 295
urn model treatment assignment, 296

author/authorship
author, 12
author citation, 12
authorship attribution, 12
authorship format, 12
conventional author citation, 56
conventional authorship, 56
corporate author citation, 57
corporate authorship, 57
masthead author listing, 153
modified conventional author citation, 158
modified conventional authorship, 158
modified corporate author citation, 158
modified corporate authorship, 158
uniform requirements for biomedical manuscripts, 293
Vancouver Convention, 298

axis
x-axis, 305
y-axis, 305

baseline
adaptive treatment assignment, 2
adjustment variable, 4
baseline, 16
baseline adaptive treatment assignment, 16
baseline characteristic, 16
baseline comparability, 16
baseline composition, 16
baseline data, 16
baseline difference, 16
baseline examination, 17
baseline observation period, 17
baseline period, 17
baseline study, 17
baseline subgroup, 17
baseline subgrouping variable, 17
baseline variable, 17
baseline visit, 17
minimum likelihood treatment assignment, 157
proportional hazard, 211
proportional hazards regression model, 211
Bayes T, 18
Bayes’ theorem, 18
Begg CB, 226
Belmont Report, 18, 137

benefit
cost–benefit analysis, 58
cost–benefit ratio, 58
risk factor, 239
risk–benefit analysis, 240
risk–benefit ratio, 240
Benford F, 19
Berkson J, 19
Bernoulli J, 19

bias
accidental bias, 1
Berksonian bias, 19
bias, 20
bias control, 20
bias free treatment assignment, 20
bias potential, 20
biased, 20
biased coin treatment assignment, 20
biased estimator, 21
cold conflict of interest, 47
detection bias, 70
differential bias, 71
digit bias, 71
digit preference, 71
effort bias, 81
feedback bias, 96
file drawer problem, 97
followup bias, 99
gender bias, 107
halo effect, 113
Hawthorne effect, 114
Heisenberg effect, 115
lead time bias, 142
measurement bias, 154
observation bias, 175
observer bias, 176
outcome reporting bias, 182
performance bias, 191
potential bias, 202
potential conflict of interest, 202
prejudice, 204
publication bias, 214
recall bias, 226
reference bias, 228
regression dilution bias, 229
representation bias, 233
response bias, 237
selection bias, 246
treatment assignment bias, 280
treatment-related analysis bias, 286
treatment-related bias, 286
treatment-related feedback bias, 286
treatment-related followup bias, 287
treatment-related selection bias, 287
unbiased, 292
unbiased estimator, 292
unmasking bias, 295
volunteer bias, 300
Bissett JK, 76
Blackburn B, 223
Bliss CI, 209

**block/blocking**
- balanced block, 15
- balanced incomplete treatment assignment block design, 15
- block, 24
- block effect, 24
- block size, 24
- block treatment design, 24
- blocked randomization, 25
- blocked treatment assignments, 25
- complete block, 42
- complete block treatment design, 42
- complete treatment assignment block design, 43
- incomplete block, 122
- incomplete complete block design, 122
- incomplete treatment assignment block design, 123
- partially balanced block, 187
- permuted block, 192
- permuted block treatment design, 192
- randomized block, 223
- randomized block design, 223
- stratified-blocked randomization, 261
- treatment assignment block, 280
- treatment assignment block effect, 280
- treatment assignment block size, 280
- unbalanced block, 292

**board**
- central institutional review board, 29
- commercial institutional review board, 40
- committee, see also, 40
- ethics review board (ERB), 86
- independent institutional review board, 123
- institutional review board (IRB), 128
- institutional review board approval, 135
- institutional review board approval renewal, 136
- institutional review board of record, 136
- local institutional review board, 146
- parent institutional review board, 187

Boissel J-P, 269
Bonferroni CE, 25
Bonferroni’s inequality, 25
Boyce WT, 79
Brain Resuscitation Clinical Trial II Study Group, 68
Breslow NE, 183
Brittain E, 142, 196
Buchwald H, 75, 76
Bursic ES, 239

Campbell GS, 76
Campos CT, 76
Cardiac Arrhythmia Suppression Trial, 142
Cardiac Arrhythmia Suppression Trial Investigators, 142
Carter SK, 154

case
- case, 27
- case finding, 27
- case history, 27
- case record, 27
- case report, 27
- case report form, 27
- case series, 27
- case study, 28
- case–cohort study, 28
- case–cohort study design, 28
- case–control study, 28
- case–control study design, 28
- incident case, 122
- index case, 124
- nested case–control study, 168
- prevalent case, 205

case–control
- case–control study, 28
- case–control study design, 28
- nested case–control study, 168

Castaneda-Zuniga WR, 76

censor/censored
- administrative censoring, 4
- censor, 28
- censoring condition, 29
- censoring variable, 29
- informative censoring, 126
- interval censoring, 132
- left censored observation, 143
- left censoring, 143
- random censoring, 221
- right censored, 238
- right censored observation, 238
- uninformative censoring, 294

center
- affiliate center, 5
- analysis center, 7
- associate center, 11
- biostatistical center, 23
- center, 29
- center representation construct, 29
- central laboratory (CL), 30
- clinical center, 33
- clinical coordinating center (CCC), 33
- coordinating center (CC), 56
- data center, 63
- data coordinating center (DCC), 64
- daughter center, 67
- distribution center, 73
- drug distribution center, 77
- key center, 139
- lead center, 142
- multicenter, 161
- multicenter study, 161
- multicenter trial, 161
- National Center for Health Statistics (NCHS), 165
- parent center, 187
primary care center, 206
procurement and distribution center, 209
procurement center, 209
project office (PO), 210
quality control center, 217
reading center (RC), 226
resource center, 236
satellite center, 243
secondary care center, 245
service center, 249
sibling center, 250
single-center, 252
single-center study, 252
single-center trial, 252
sister center, 253
statistical center, 258
study center, 262
study center director, 262
support center, 268
tertiary care center, 274
treatment coordinating center (TCC), 281
Chalmers TC, 76, 101, 223
chart
flowchart, 98
record, see also, 227
Clarke M, 101
clinic
affiliate clinic, 5
associate clinic, 11
center, see also, 29
clinic, 33
clinic close-out design, 33
clinic preference treatment design, 33
clinic probation, 33
clinic start-up design, 33
clinic study roll, 33
daughter clinic, 67
enrolling clinic, 83
following clinic, 99
lead clinic, 142
parent clinic, 187
receiving clinic, 226
satellite clinic, 243
sibling clinic, 250
sister clinic, 253
study clinic, 263
study clinic coordinator, 263
study clinic director, 263
study clinic monitor, 263
transfer clinic, 278
transferring clinic, 278
treating clinic, 279
close-out
anniversary closing date, 9
anniversary date patient close-out, 9
clinic close-out design, 33
close of followup, 36
close-out design, 36
close-out examination, 36
close-out followup visit, 36
close-out stage, 36
common closing date, 40
patient close-out, 189
patient close-out examination, 189
patient followup close-out design, 189
post-close-out followup visit, 201
trial close-out design, 287
Cochrane AL, 80
coefficient
binomial coefficient, 22
coefficient of association, 38
coefficient of variation (CoV), 38
correlation coefficient, 57
multiple correlation coefficient, 162
partial correlation coefficient, 187
Pearson product-moment correlation coefficient, 191
rank correlation coefficient, 225
regression coefficient, 229
cohort
birth cohort, 23
case–cohort study, 28
case–cohort study design, 28
closed cohort, 36
cohort, 39
cohort analysis, 39
cohort effect, 39
cohort study, 39
concurrent cohort study, 45
dynamic cohort, 78
fixed cohort, 98
followup cohort, 99
nonconcurrent cohort study, 169
open cohort, 179
committee
advisory-review & trt effects monitoring committee (ARTEMC), 5
advisory-review committee (ARC), 5
analysis committee, 7
committee, 40
committee member, 40
data and safety monitoring committee (DSMC), 63
data monitoring committee (DMC), 65
editorial review committee, 80
ethics committee, 86
executive committee (EC), 87
external advisory committee (EAC), 91
external committee member, 91
external treatment effects monitoring committee, 91
Helsinki committee, 115
institutional animal care and use committee (IACUC), 128
internal committee member, 131
committee (Continued)
  internal treatment effects monitoring committee, 131
  International Committee of Medical Journal Editors, 293
  key committee, 139
  lay committee member, 142
  masked treatment effects monitoring committee, 152
  monitoring committee, 159
  NIH Clinical Trials Committee, 9
  operations committee, 180
  performance monitoring committee, 192
  publication committee, 214
  safety committee, 241
  safety monitoring committee, 241
  steering committee (SC), 258
  study committee, 263
  Teratology Society Public Affairs Committee, 78
  treatment effects and performance monitoring committee, 282
  treatment effects monitoring and analysis committee, 282
  treatment effects monitoring committee (TEMC), 282
  unmasked treatment effects monitoring committee, 295
  writing committee, 304

comparison
  a posteriori treatment comparison, 1
  a priori treatment comparison, 1
  ad hoc subgroup comparison, 2
  comparison group, 41
  comparison treatment, 41
  designed subgroup comparison, 70
  designed treatment comparison, 70
  direct treatment comparison, 72
  indirect treatment comparison, 125
  mixed treatment comparison, 157
  multiple comparisons, 161
  paired comparisons, 185
  post hoc treatment comparison, 201
  primary comparison, 206
  primary treatment comparison, 207
  primary treatment group comparison, 207
  principal treatment comparison, 208
  secondary treatment comparison, 246
  subgroup comparison, 267
  test-control treatment comparison, 276
  treatment group comparison, 283
  valid comparison, 298

compliance
  adherence, see also, 3
  compliance, 44
  compliance measure, 45
  data collection compliance measure, 63
  followup compliance, 99
  followup compliance measure, 99
Index

**consent form**
approved consent form, 10
Consolidated Standards of Reporting Trials (CONSORT), 302

**contract**
contract, 53
contract office, 53
contract officer, 54
contract proposal, 54
contract research organization (CRO), 54
cost-reimbursement contract, 58
fixed-cost contract, 98
grant, see also, 109
research contract proposal, 235
sole source contract, 254
subcontract, 266
subcontractor, 267

**control**
active control treatment, 2
best medical judgment control treatment, 19
bias control, 20
case–control study, 28
case–control study design, 28
concurrent control, 45
concurrent control group, 45
control, 54
control drug, 54
control group, 54
control patient, 54
control treatment, 54
control-assigned, 54
control-assigned group, 54
control-assigned patient, 54
control-treated, 55
control-treated group, 55
control-treated patient, 55
historical control, 115
historical control group, 116
historical controls, 116
inactive control treatment, 121
literature control, 146
matched control, 153
negative control, 167
negative control treatment, 167
nested case–control study, 168
nil treatment control, 169
nonconcurrent control, 169
nonparallel control, 171
nontreatment control, 172
null treatment control, 172
observation control, 175
observation control treatment, 175
parallel control, 186
placebo control, 196
placebo-control treatment, 197
population controls, 199
positive control, 200
positive control treatment, 200
quality control, 217
quality control center, 217
randomized control, 223
randomized control trial (RCT), 223
randomly selected control, 224
standard control treatment, 256
test-control treatment comparison, 276
test-control treatment difference, 276
trace control treatment, 278
variance control, 299
wait-list control treatment, 301
yoked control, 305

**controlled**
adequate and well-controlled, 2
adequate and well-controlled trial, 3
controlled, 55
controlled clinical trial, 55
controlled experiment, 55
controlled treatment assignment, 56
controlled trial, 56
controlled variable, 56
placebo-controlled trial, 197
randomized controlled trial (RCT), 224
uncontrolled, 292
uncontrolled clinical trial, 292
uncontrolled treatment assignment, 292
uncontrolled trial, 292
uncontrolled variable, 292
well-controlled, 302

**coordinating center**
analysis center, 7
biostatistical center, 23
center, see also, 29
clinical coordinating center (CCC), 33
coordinating center (CC), 56
data center, 63
data coordinating center (DCC), 64
resource center, 236
statistical center, 258
support center, 268
treatment coordinating center (TCC), 281
Cornfield J, 18, 144, 231
Coronary Artery Surgery Study, 262
Coronary Drug Project, 43, 142, 185, 196, 210, 252, 255
Coronary Drug Project Research Group, 43, 142, 196

**correlation**
correlation, 57
correlation coefficient, 57
correlation matrix, 58
illusory correlation, 120
Kendall’s tau, 139
linear correlation, 145
multiple correlation coefficient, 162
negative correlation, 167
partial correlation, 187
partial correlation coefficient, 187
correlation (Continued)
Pearson product-moment correlation coefficient, 191
positive correlation, 200
rank correlation, 225
rank correlation coefficient, 225
serial correlation, 248
Spearman’s rank correlation, 255
spurious correlation, 256
statistical correlation, 258

cost
cost–benefit analysis, 58
cost–benefit ratio, 58
cost–effectiveness analysis, 58
cost–reimbursement contract, 58
cost–utility analysis, 58
direct cost, 71
facilities and administrative cost, 93
fixed-cost contract, 98
indirect cost, 124
indirect research cost, 125
overhead, 183
total cost, 277

covariance
analysis of covariance (AnoCo), 8
covariance, 58
time-dependent covariate, 277
time-independent covariate, 277
time-invariant covariate, 277
treatment dependent covariate, 281
treatment independent covariate, 284
variance–covariance matrix), 299
Cox DR, 59, 183

crossover
complete crossover treatment design, 43
complete treatment crossover, 43
crossover treatment, 60
crossover treatment design, 60
crossover treatment structure, 60
crossover trial, 60
incomplete crossover treatment design, 122
multi-period crossover treatment design, 160
n-period crossover design, 165
treatment crossover, 281
treatment crossover trial, 281
two-period crossover design, 289

curve
bell-shaped curve, 18
cumulative mortality curve, 61
curve fit, 61
curve fitting, 61
dempirical curve, 83
Gompertz’s curve, 108
growth curve, 111
j-shaped curve, 137
Kaplan–Meier curve, 138
logistic curve, 147
receiver operating characteristic curve (RoC), 226
regression curve, 229
s-shaped curve, 241
survival curve, 269
u-shaped curve, 291

data
adjusted data, 3
admissible data, 4
aggregate data, 6
aggregate patient data, 6
aggregate patient data meta-analysis, 6
analysis data edit, 8
analysis database, 8
analysis dataset, 8
anonymized data, 9
anonymous data, 9
baseline data, 16
bolus data flow, 25
categorical data, 28
centralized data analysis, 30
centralized data entry, 30
centralized data system, 30
centralized database, 30
clean data, 32
clustered data, 37
completeness of data, 44
conditional data item, 46
confirmatory data analysis, 46
continuous data, 53
continuous data flow, 53
crude data, 60
data, 63
data and safety monitoring committee (DSMC), 63
data audit, 63
data bank, 63
data center, 63
data coding, 63
data collection compliance measure, 63
data collection design, 63
data collection mask, 63
data collection protocol, 64
data collection schedule, 64
data collection site, 64
data coordinating center (DCC), 64
data coordinator, 64
data dictionary, 64
data dredging, 64
data edit, 64
data editing, 64
data entry, 64
data field, 65
data file, 65
data flow, 65
data form, 65
data form walk-through, 65
data freeze, 65
data generation, 65
data generation site, 65
data item, 65
data item logic, 65
data keying, 65
data management, 65
data monitoring, 65
data monitoring committee (DMC), 65
data monitoring report, 65
data processing, 66
data purge, 66
data query, 66
data record, 66
data reduction, 66
data sharing, 66
data simple trial, 66
data snapshot, 66
data system, 66
data transcription, 66
data transformation, 66
data type, 67
data use agreement, 67
database, 67
database management system, 67
dataset, 67
deidentified data, 69
demographic data, 69
dependent double data entry, 69
detached data sharing, 70
direct data entry, 71
dirty data, 72
discrete data, 73
distributed data analysis, 73
distributed data entry, 73
distributed data system, 73
distributed database, 73
double data entry, 75
edited data, 80
electronic data capture, 82
explicit data item logic, 90
exploratory data analysis, 90
external data sharing, 91
fabricated data, 93
final data analysis, 97
final dataset, 100
followup data, 100
followup data collection visit, 100
frozen data, 103
frozen dataset, 103
goto data item, 109
group data, 110
group sequential interim data analysis, 111
grouped data, 111
hierarchical database, 115
identifiable data, 119
identified data, 119
identifier data, 119
implicit data item logic, 120
inadmissible data, 121
independent double data entry, 123
individual patient data, 126
individual patient data meta-analysis, 126
instruction data item, 128
intelligent data entry, 129
interim data analysis, 130
interim dataset, 130
internal data sharing, 131
interval data, 132
keyless data recording, 139
limited dataset, 145
limited use dataset, 145
linkable data, 146
linked data, 146
mandated data sharing, 151
masked data analysis, 152
masked data collection, 152
metadata, 156
metric data, 156
missed data, 157
negative data, 167
nominal data, 169
nonmetric data, 171
on-line data acquisition, 178
on-line data entry, 178
ordinal data, 181
original data, 182
paper data form, 186
paperless data entry, 186
partnership data sharing, 188
PC-based data entry, 190
positive data, 200
primary data, 206
primary data analysis, 206
public use dataset, 214
qualitative data, 217
quantitative data, 218
quasi-independent double data entry, 218
raw data, 226
real-time data entry, 226
redacted data, 228
relational database, 230
required data, 234
secondary data, 245
secondary data analysis, 245
sequential data analysis, 247
shared data, 249
skip data item, 253
source data, 254
source document, 254
stop data item, 260
study data, 263
study database, 263
timeliness of data, 277
truncated data, 288
unadjusted data, 291
unedited data, 293
unidentifiable data, 293
unlinkable data, 294
data (Continued)
voluntary data sharing, 300
web-based data entry, 301

data analysis
centralized data analysis, 30
confirmatory data analysis, 46
data analysis mask, 63
distributed data analysis, 73
exploratory data analysis, 90
final data analysis, 97
fishing expedition, 98
group sequential interim data analysis, 111
interim data analysis, 130
masked data analysis, 152
primary data analysis, 206
secondary data analysis, 245
sequential data analysis, 247

data collection
data collection mask, 63
data collection schedule, 64
data collection site, 64
followup data collection visit, 100
masked data collection, 152

data type
adjusted data, 3
aggregate data, 6
baseline data, 16
categorical data, 28
clean data, 32
continuous data, 53
crude data, 60
dirty data, 72
discrete data, 73
edited data, 80
followup data, 100
group data, 110
grouped data, 111
interval data, 132
metric data, 156
nominal data, 169
nonmetric data, 171
ordinal data, 181
primary data, 206
qualitative data, 217
quantitative data, 218
raw data, 226
secondary data, 245
study data, 263
truncated data, 288
unadjusted data, 291
unedited data, 293

study database, 263
Delaney JJ, 69
DeMets DL, 111
Department of Health and Human Services (DHHS), 53, 109
Department of Health, Education, and Welfare (DHEW), 53, 109
design
adaptive study design, 2
balanced incomplete treatment assignment block design, 15
balanced treatment design, 15
block treatment design, 24
case–cohort study design, 28
case–control study design, 28
clinic close-out design, 33
clinic preference treatment design, 33
clinic start-up design, 33
close-out design, 36
closed sequential design, 37
complete block treatment design, 42
complete crossover treatment design, 43
complete factorial treatment design, 43
complete treatment assignment block design, 43
complex treatment design, 44
continual assessment dosage design, 53
crossed treatment design, 59
crossover treatment design, 60
data collection design, 63
design, 69
design and funding stage, 70
design effect, 70
design stage, 70
design synopsis, 70
design unit, 70
design variable, 70
designed subgroup comparison, 70
dosage design, 74
double placebo treatment design, 75
enrollment design, 83
experimental design, 89
factorial treatment design, 94
fixed randomization design, 98
fixed sample size design, 98
fixed study design, 98
fixed treatment assignment design, 98
Greco-Latin square treatment design, 110
group sequential design, 111
incomplete block design, 122
incomplete block treatment design, 122
incomplete crossover treatment design, 122
incomplete factorial treatment design, 122
incomplete treatment assignment block design, 123
Latin square treatment design, 141
modified Fibonacci sequence dosage design, 158
monitoring design, 159
multi-period crossover treatment design, 160
multi-stage design, 160

database
analysis database, 8
centralized database, 30
database management system, 67
distributed database, 73
hierarchical database, 115
relational database, 230
multi-study design, 160
multi-trial design, 160
multiple placebo treatment design, 163
n-period crossover design, 165
open sequential design, 180
paired treatment design, 185
parallel group design, 186
parallel treatment design, 186
patient followup close-out design, 189
permutated block treatment design, 192
physician preference treatment design, 195
preference treatment design, 203
randomization design, 223
randomized block design, 223
repeated measures design, 231
risk concentration design, 239
sample size design, 242
sampling design, 242
sequential design, 248
sequential dosage design, 248
sequential sample size design, 248
simple treatment design, 251
single placebo treatment design, 252
split-plot design, 255
start-up design, 258
stepped wedge design, 259
study design, 263
switchback crossover design, 270
treatment sequential dosage design, 278
treatment assignment design, 280
treatment design, 281
trial close-out design, 287
trial start-up design, 288
two-period crossover design, 289
two-stage design, 289
unit sequential design, 294
up–down sequential dosage design, 296
deviation/deviate
deviation, 71
development from mean, 71
mean absolute deviation, 154
mean deviation, 154
normal deviate, 172
protocol deviation, 212
standard deviation (SD, sd), 256
standardized normal deviate, 257
device
device trial, 71
humanitarian device exemption (HDE), 117
humanitarian use device (HUD), 117
Investigational Device Exemption (IDE), 133
Investigational Device Exemption Application (IDEA), 133
Diabetic Retinopathy Study, 109
Diaconis P, 25, 137
digit
cHECK digit, 31
digit bias, 71
digit preference, 71
Id check digit, 119
random digit dialing, 221
significant digit, 251
disease
clinical disease, 33
distribution
bell-shaped distribution, 18
bimodal distribution, 21
binomial distribution, 22
bivariate distribution, 23
bivariate normal distribution, 23
chi-square distribution, 31
conditional distribution, 46
cumulative frequency distribution, 60
direct distribution of funds, 71
distribution center, 73
distribution function, 73
distribution-free method, 73
exponential distribution, 90
F distribution, 93
fiducial distribution, 96
frequency distribution, 103
gamma distribution, 107
hypergeometric distribution, 117
indirect distribution of funds, 124
j-shaped distribution, 137
joint distribution, 137
joint frequency distribution, 137
left skew distribution, 143
lognormal distribution, 147
marginal distribution, 151
multimodal distribution, 161
normal distribution, 172
percentage distribution, 191
platykurtic distribution, 198
Poisson distribution, 199
procurement and distribution center, 209
right skew distribution, 238
sampling distribution, 242
skew(ed) distribution, 253
standard distribution, 256
standard normal distribution, 257
Student’s t distribution, 262
t distribution, 273
unconditional distribution, 292
uniform distribution, 293
univariate distribution, 294
Dixon WJ, 296
dose
continual assessment dosage design, 53
dosage, 74
dosage design, 74
dose escalation, 74
dose ranging study, 74
dose response, 74
dose schedule, 74
dose (Continued)
   homeopathic dose, 116
   inactive treatment dose, 121
   infectious dose (ID), 126
   infectious median dose, 126
   lethal dose (LD), 143
   lethal median dose, 143
   loading dose, 146
   maximum tolerable dose (MTD), 154
   median dose, 154
   modified Fibonacci sequence dosage design, 158
   traditional sequential dosage design, 278
   treatment dosage, 281
   treatment dose, 282
   up–down sequential dosage design, 296

drug
   Abbreviated New Drug Application (ANDA), 1
   adverse drug experience, 4
   adverse drug reaction (ADR), 5
   approved drug, 10
   bin number drug system, 21
   breakthrough drug, 26
   combination drug, 40
   control drug, 54
   drug, 76
   drug distribution center, 77
   Drug Efficacy Study (DES), 77
   Drug Efficacy Study Implementation (DESI), 77
   drug interaction, 77
   drug lag, 77
   drug reaction, 77
   drug resistance, 78
   emergency use IND, 83
   ethical drug firm, 86
   experimental drug, 89
   Food and Drug Administration (FDA), 100
   generic drug, 108
   grandfather drug, 109
   IND cross-reference, 123
   IND number, 123
   IND trial, 123
   innovator drug, 127
   investigational new drug, 133
   Investigational New Drug Application (INDA), 133
   investigational new drug safety report, 134
   investigator IND, 134
   med Id number drug system, 154
   new drug, 168
   New Drug Application (NDA), 168
   orphan drug, 182
   over-the-counter drug, 183
   phase I drug trial, 193
   phase I/II drug trial, 193
   phase II drug trial, 193
   phase II/III drug trial, 193
   phase III drug trial, 194
   phase IV drug trial, 194
   pioneer drug, 195
   prescription drug, 204
   Prescription Drug User Fee Act, 204
   pro-drug, 208
   proprietary drug, 211
   serious adverse drug experience, 249
   teratogenic risk classification of approved drugs, 78
   toxic drug reaction, 278
   treatment IND, 284
   treatment investigational new drug, 284
   unexpected adverse drug experience, 293

Drug Efficacy Study (DES), 77
Drug Efficacy Study Implementation (DESI), 77
DuBois D, 169
DuBois EF, 169
Dupont WD, 144

Eberlein K, 21
Edmiston WA, 76

effect
   adverse side effect, 5
   adverse treatment effect, 5
   advisory-review & trt effects monitoring committee (ARTEMC), 5
   antagonistic treatment effect, 9
   apartheid treatment effects monitoring, 9
   asymmetrical treatment effects monitoring, 12
   beneficial effect, 19
   beneficial treatment effect, 19
   block effect, 24
   carryover effect, 27
   cause and effect, 28
   cohort effect, 39
   confounded effect, 47
   cost-effectiveness analysis, 58
   design effect, 70
   effect modifier, 80
   effect size, 80
   effective sample size, 80
   effectiveness, 80
   effectiveness trial, 80
   expected effective sample size, 88
   external treatment effects monitoring committee, 91
   fixed-effects model, 98
   generally recognized as safe and effective (GRASE), 108
   generation effect, 108
   halo effect, 113
   harmonic mean, 114
   healthy worker effect, 115
   Heisenberg effect, 115
   internal treatment effects monitoring committee, 131
   main effect, 151
   masked treatment effects monitoring, 152
   masked treatment effects monitoring committee, 152
masked treatment effects monitoring report, 152
mixed-effects model, 157
negative effect, 167
negative treatment effect, 167
net treatment effect, 168
nil treatment effect, 169
observed effective sample size, 176
observed treatment effect, 176
placebo effect, 196
placebo treatment effect, 197
positive effect, 200
positive treatment effect, 201
preventative effect, 205
protective effect, 211
random effect, 221
random-effects model, 222
safe and effective, 241
side effect, 250
symmetrical treatment effects monitoring, 270
synergistic treatment effect, 270
toxic side effect, 278
treatment assignment block effect, 280
treatment effect, 282
treatment effects and performance monitoring committee, 282
treatment effects monitoring, 282
treatment effects monitoring and analysis committee, 282
treatment effects monitoring committee (TEMC), 282
treatment effects monitoring report, 283
treatment side effect, 285
unmasked treatment effects monitor, 295
unmasked treatment effects monitoring, 295
unmasked treatment effects monitoring committee, 295
unmasked treatment effects monitoring report, 295
Efron B, 1, 25, 137
end point, endpoint, see outcome, 83
enrollment
co-enrollment, 37
concurrent enrollment, 45
enrollment, 83
enrollment design, 83
enrollment goal, 84
enrollment override, 84
enrollment quota, 84
enrollment suspension, 84
expected enrollment, 88
nonconcurrent enrollment, 170
observed enrollment, 176
patient enrollment, 189
patient enrollment goal, 189
patient enrollment period, 189
patient enrollment quota, 189
recruitment and enrollment stage, 228
time of enrollment, 277
epidemiology
clinical epidemiology, 33
epidemiological study, 84
epidemiology, 84
experimental epidemiology, 89
pharmacoepidemiology, 193
error
alpha error, 6
conditional type II error, 46
error, 85
error margin, 85
error term, 85
error variance, 85
experimental error, 89
linkage error, 146
mean square error, 154
measurement error, 154
observer error, 176
probable error, 209
random error, 221
root-mean square error, 240
standard error (SE, se), 256
systematic error, 270
trial and error, 287
type I error, 289
type II error, 289
type III error, 289
estimate
bootstrap estimate, 25
estimate, 85
estimated sample size, 86
generalized estimating equation, 108
interval estimate, 132
linear estimate, 145
point estimate, 199
pooled estimate, 199
ratio estimate, 225
regression estimate, 230
estimator
biased estimator, 21
consistent estimator, 51
estimator, 86
robust estimator, 240
unbiased estimator, 292
ethics review board (ERB), 86
event
adverse event, 5
clinical event, 34
composite event, 45
composite outcome event, 45
critical event, 59
event rate, 87
independent event, 123
mutually exclusive events, 163
outcome event, 182
primary event, 206
reportable event, 232
reported event, 233
event (Continued)
  secondary event, 245
  unusual event, 296
  unusual event log, 296

examination
  baseline examination, 17
  close-out examination, 36
  examination, 87
  final patient examination, 97
  National Health and Nutrition Examination Survey (NHANES), 165
  patient close-out examination, 189
  patient examination, 189
  preassignment examination, 203
  prerandomization examination, 204
  pretreatment examination, 205
  study examination, 263

experiment
  controlled experiment, 55
  experiment, 88
  experimental design, 89
  experimental drug, 89
  experimental epidemiology, 89
  experimental error, 89
  experimental treatment, 89
  experimental trial, 89
  experimental unit, 89
  experimental variable, 89
  factorial experiment, 94
  fortuitous experiment, 101
  natural experiment, 166
  parallel experiment, 186
  social experiment, 254

FDA-related term
  emergency use IND, 83
  investigator IND, 134
  medical device class, 155
  Premarket Approval Application, 204

FDA-related terms
  Abbreviated New Drug Application (ANDA), 1
  adequate and well-controlled, 2
  adequate and well-controlled trial, 3
  adverse drug experience, 4
  adverse drug reaction (ADR), 5
  adverse side effect, 5
  antagonistic treatment effect, 9
  approved drug, 10
  audit for cause, 12
  bioavailability study, 22
  bioavailable, 22
  bioequivalent, 22
  biologic product, 23
  biological license application, 22
  black box warning, 23
  blacklist, 23
  case report, 27
  case report form, 27
  clinical hold, 34
  compassionate use, 41
  controlled trial, 56
  crossover trial, 60
  Dear Dr letter, 67
  Delaney Amendment, 69
  device trial, 71
  drug, 76
  Drug Efficacy Study (DES), 77
  Drug Efficacy Study Implementation (DESI), 77
  drug interaction, 77
  drug lag, 77
  drug reaction, 77
  effectiveness trial, 80
  efficacy trial, 81
  electronic record, 82
  electronic signature, 82
  emergency use, 82
  expanded access, 88
  expanded availability, 88
  experimental drug, 89
  explanatory trial, 90
  FDA form 1571: Investigational new drug application, 94
  FDA Form 1572: Statement of investigator, 94
  FDA Form 3500: MedWatch, 95
  FDA Form 356h: Appl to market new drug, biologic, or antibiotic, 95
  Food and Drug Administration (FDA), 100
  generally recognized as safe and effective (GRASE), 108
  generic drug, 108
  grandfather drug, 109
  harmonization, 114
  homeopathic dose, 116
  humanitarian device exemption (HDE), 117
  humanitarian use device (HUD), 117
  IND cross-reference, 123
  IND number, 123
  IND trial, 123
  innovator drug, 127
  Investigational Device Exemption (IDE), 133
  Investigational Device Exemption Application (IDEA), 133
  investigational new drug, 133
  Investigational New Drug Application (INDA), 133
  investigational new drug safety report, 134
  Kefauver–Harris Act of 1962, 138
  label insert, 141
  least burdensome, 143
  licensure trial, 144
  median dose, 154
  medical device, 154
  medical device, class I, 155
  medical device, class II, 155
  medical device, class III, 155
  new drug, 168
New Drug Application (NDA), 168
off-label, 177
off-label use, 177
open label trial, 180
open trial, 180
orphan drug, 182
over-the-counter drug, 183
parallel track, 186
phase I drug trial, 193
phase I/II drug trial, 193
phase II drug trial, 193
phase II/III drug trial, 193
phase III drug trial, 194
phase III trial, 194
phase IV drug trial, 194
pioneer drug, 195
pivotal trial, 195
post-marketing surveillance, 201
pragmatic trial, 202
premarket approval, 204
Prescription Drug User Fee Act, 204
Product License Application (PLA), 209
proprietary drug, 211
safety report, 242
serious adverse drug experience, 249
sponsor, 255
substantial evidence, 268
synergistic treatment effect, 270
therapeutic index, 276
therapeutic range, 276
toxic drug reaction, 278
toxic side effect, 278
treatment IND, 284
treatment investigational new drug, 284
unexpected adverse drug experience, 293
warning letter, 95
well-controlled, 302
vaccine, 297
valid scientific evidence, 298
Fellegi IP, 31
Feller W, 19, 25
Fergusson D, 32, 60
Fisher L, 53
Fisher RA, 96, 97, 144
Fitch LL, 76
followup
active followup, 2
close of followup, 36
close-out followup visit, 36
concurrent followup, 45
concurrent followup study, 45
direct followup, 71
followup, 99
followup bias, 99
followup cohort, 99
followup compliance, 99
followup compliance measure, 99
followup data, 100
followup data collection visit, 100
followup observation, 100
followup period, 100
followup schedule, 100
followup stage, 100
followup study, 100
followup variable, 100
followup visit, 100
followup visit schedule, 100
indirect followup, 124
interim followup, 130
interim followup visit, 130
length of followup, 143
long-term followup, 148
losses to followup, 148
lost to followup, 148
nonconcurrent followup study, 170
passive followup, 188
patient followup, 189
patient followup close-out design, 189
post-close-out followup visit, 201
post-treatment followup, 201
post-treatment followup period, 201
post-trial followup, 201
post-trial followup stage, 202
post-trial followup visit, 202
prospective followup study, 211
regular followup visit, 230
required followup, 235
required followup visit, 235
retrospective followup, 237
retrospective followup study, 237
scheduled followup visit, 243
short-term followup, 250
treatment and followup period, 279
treatment and followup stage, 279
treatment application and adjustment followup visit, 279
treatment-related followup bias, 287
unscheduled followup, 296
unscheduled followup visit, 296
Food and Drug Administration, 114
Food and Drug Administration (FDA), 1, 2, 4, 10, 30,
Establishment License Application (ELA), 85
FDA form 1571: Investigational new drug application, 94
FDA Form 1572: Statement of investigator, 94
FDA Form 3500: MedWatch, 95
FDA Form 356h: Appl to market new drug, biologic, or antibiotic, 95
International Conference on Harmonisation, 131
phase of trial, 194
recall, 226
Fost N, 68
Freedman B, 34
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freiman JA</td>
<td>101</td>
</tr>
<tr>
<td>frequency</td>
<td></td>
</tr>
<tr>
<td>class frequency</td>
<td>32</td>
</tr>
<tr>
<td>cumulative frequency</td>
<td>60</td>
</tr>
<tr>
<td>cumulative frequency...</td>
<td>60</td>
</tr>
<tr>
<td>frequency</td>
<td>102</td>
</tr>
<tr>
<td>frequency distribution</td>
<td>103</td>
</tr>
<tr>
<td>frequency matching</td>
<td>103</td>
</tr>
<tr>
<td>frequency polygon</td>
<td>103</td>
</tr>
<tr>
<td>frequency table</td>
<td>103</td>
</tr>
<tr>
<td>joint frequency distribution</td>
<td>137</td>
</tr>
<tr>
<td>relative frequency</td>
<td>231</td>
</tr>
<tr>
<td>Friedman B</td>
<td>296</td>
</tr>
<tr>
<td>function</td>
<td></td>
</tr>
<tr>
<td>bivariate density function</td>
<td>23</td>
</tr>
<tr>
<td>distribution function</td>
<td>73</td>
</tr>
<tr>
<td>exponential function</td>
<td>90</td>
</tr>
<tr>
<td>gamma function</td>
<td>107</td>
</tr>
<tr>
<td>hazard function</td>
<td>114</td>
</tr>
<tr>
<td>joint density function</td>
<td>137</td>
</tr>
<tr>
<td>joint probability function</td>
<td>137</td>
</tr>
<tr>
<td>likelihood function</td>
<td>144</td>
</tr>
<tr>
<td>logarithmic function</td>
<td>147</td>
</tr>
<tr>
<td>logistic function</td>
<td>147</td>
</tr>
<tr>
<td>power function</td>
<td>202</td>
</tr>
<tr>
<td>probability density function</td>
<td>209</td>
</tr>
<tr>
<td>probability distribution function (pdf)</td>
<td>209</td>
</tr>
<tr>
<td>probability mass function</td>
<td>209</td>
</tr>
<tr>
<td>funding</td>
<td></td>
</tr>
<tr>
<td>award statement</td>
<td>13</td>
</tr>
<tr>
<td>centralized funding</td>
<td>30</td>
</tr>
<tr>
<td>competitive funding</td>
<td>42</td>
</tr>
<tr>
<td>competitive range</td>
<td>42</td>
</tr>
<tr>
<td>competitive renewal</td>
<td>42</td>
</tr>
<tr>
<td>consortium funding</td>
<td>52</td>
</tr>
<tr>
<td>consortium funding agreement</td>
<td>52</td>
</tr>
<tr>
<td>consortium funding award</td>
<td>52</td>
</tr>
<tr>
<td>contract</td>
<td>53</td>
</tr>
<tr>
<td>contract office</td>
<td>53</td>
</tr>
<tr>
<td>contract officer</td>
<td>54</td>
</tr>
<tr>
<td>contract proposal</td>
<td>54</td>
</tr>
<tr>
<td>cooperative agreement</td>
<td>56</td>
</tr>
<tr>
<td>Cooperative Research and Development Agreement (CRADA)</td>
<td>56</td>
</tr>
<tr>
<td>core funding</td>
<td>57</td>
</tr>
<tr>
<td>cost reimbursement</td>
<td>58</td>
</tr>
<tr>
<td>cost-reimbursement contract</td>
<td>58</td>
</tr>
<tr>
<td>design and funding stage</td>
<td>70</td>
</tr>
<tr>
<td>direct funding</td>
<td>71</td>
</tr>
<tr>
<td>direct funding award</td>
<td>71</td>
</tr>
<tr>
<td>distributed funding</td>
<td>73</td>
</tr>
<tr>
<td>extramural funding</td>
<td>91</td>
</tr>
<tr>
<td>fixed cost</td>
<td>98</td>
</tr>
<tr>
<td>funding agency</td>
<td>104</td>
</tr>
<tr>
<td>funding award</td>
<td>104</td>
</tr>
<tr>
<td>funding cycle</td>
<td>104</td>
</tr>
<tr>
<td>funding mode</td>
<td>104</td>
</tr>
<tr>
<td>funding period</td>
<td>104</td>
</tr>
<tr>
<td>funding proposal</td>
<td>104</td>
</tr>
<tr>
<td>funding stage</td>
<td>104</td>
</tr>
<tr>
<td>incremental funding</td>
<td>123</td>
</tr>
<tr>
<td>indirect funding</td>
<td>125</td>
</tr>
<tr>
<td>indirect funding award</td>
<td>125</td>
</tr>
<tr>
<td>intramural funding</td>
<td>133</td>
</tr>
<tr>
<td>noncompetitive proposal</td>
<td>169</td>
</tr>
<tr>
<td>noncompetitive renewal</td>
<td>169</td>
</tr>
<tr>
<td>recompete</td>
<td>226</td>
</tr>
<tr>
<td>recompetition</td>
<td>227</td>
</tr>
<tr>
<td>renewal</td>
<td>231</td>
</tr>
<tr>
<td>small business set-aside</td>
<td>254</td>
</tr>
<tr>
<td>sole source contract</td>
<td>254</td>
</tr>
<tr>
<td>sources sought request</td>
<td>255</td>
</tr>
<tr>
<td>unit payment</td>
<td>294</td>
</tr>
<tr>
<td>Galton F</td>
<td>229, 230</td>
</tr>
<tr>
<td>Gent M</td>
<td>90, 129, 151, 202</td>
</tr>
<tr>
<td>Glass GV</td>
<td>156</td>
</tr>
<tr>
<td>Glass KC</td>
<td>32, 60</td>
</tr>
<tr>
<td>Glaucoma Laser Trial</td>
<td>109, 185</td>
</tr>
<tr>
<td>Glaucoma Laser Trial Research Group</td>
<td>185</td>
</tr>
<tr>
<td>Gompertz B</td>
<td>108</td>
</tr>
<tr>
<td>Gordis L</td>
<td>12</td>
</tr>
<tr>
<td>grant</td>
<td></td>
</tr>
<tr>
<td>contract</td>
<td>53</td>
</tr>
<tr>
<td>grant</td>
<td>109</td>
</tr>
<tr>
<td>grant proposal</td>
<td>110</td>
</tr>
<tr>
<td>grants office</td>
<td>110</td>
</tr>
<tr>
<td>grants officer</td>
<td>110</td>
</tr>
<tr>
<td>research grant</td>
<td>235</td>
</tr>
<tr>
<td>research grant application</td>
<td>235</td>
</tr>
<tr>
<td>research grant proposal</td>
<td>236</td>
</tr>
<tr>
<td>U01 NIH grant</td>
<td>291</td>
</tr>
<tr>
<td>U10 NIH grant</td>
<td></td>
</tr>
<tr>
<td>graphic display</td>
<td></td>
</tr>
<tr>
<td>bar diagram</td>
<td>16</td>
</tr>
<tr>
<td>box plot</td>
<td>25</td>
</tr>
<tr>
<td>circle graph</td>
<td>32</td>
</tr>
<tr>
<td>citation map</td>
<td>32</td>
</tr>
<tr>
<td>CONSORT chart</td>
<td>51</td>
</tr>
<tr>
<td>flowchart</td>
<td>98</td>
</tr>
<tr>
<td>forest plot</td>
<td>101</td>
</tr>
<tr>
<td>funnel graph</td>
<td>104</td>
</tr>
<tr>
<td>Gantt chart</td>
<td>107</td>
</tr>
<tr>
<td>histogram</td>
<td>115</td>
</tr>
<tr>
<td>isometric graph</td>
<td>136</td>
</tr>
<tr>
<td>Kaplan–Meier curve</td>
<td>138</td>
</tr>
<tr>
<td>scatter diagram</td>
<td>243</td>
</tr>
<tr>
<td>Venn diagram</td>
<td>299</td>
</tr>
<tr>
<td>group</td>
<td></td>
</tr>
<tr>
<td>ad hoc subgroup</td>
<td>2</td>
</tr>
<tr>
<td>ad hoc subgroup comparison</td>
<td>2</td>
</tr>
<tr>
<td>baseline subgroup</td>
<td>17</td>
</tr>
<tr>
<td>baseline subgrouping variable</td>
<td>17</td>
</tr>
<tr>
<td>collaborative group</td>
<td>40</td>
</tr>
<tr>
<td>concurrent comparison group</td>
<td>41</td>
</tr>
<tr>
<td>concurrent control group</td>
<td>45</td>
</tr>
<tr>
<td>control group</td>
<td>54</td>
</tr>
</tbody>
</table>
control-assigned group, 54
control-treated group, 55
designed subgroup comparison, 70
exposed group, 90
focus group, 99
group data, 110
group matching, 110
group randomization, 110
group sequential, 110
group sequential design, 111
group sequential interim data analysis, 111
grouped data, 111
historical control group, 116
index group, 124
investigative group (IG), 134
parallel group design, 186
placebo group, 196
placebo-assigned group, 197
placebo-treated group, 198
primary treatment group comparison, 207
reference group, 228
research group, 236
review group, 238
specified subgroup, 255
study group, 264
study treatment group, 266
study-treated group, 266
subgroup, 267
subgroup analysis, 267
subgroup comparison, 267
subgroup difference, 267
subgroup treatment difference, 267
subgrouping cutpoint, 267
subgrouping variable, 268
test group, 274
test-assigned group, 276
test-treated group, 276
treatment group, 283
treatment group comparison, 283
within-group sum of squares, 303

Howard SV, 183
Huber PJ, 302
Hunter DW, 76
Hutton B, 32, 60

**hypothesis**
alternative hypothesis, 7
composite hypothesis, 45
hypothesis, 117
null hypothesis, 172
one-tailed alternative hypothesis, 179
research hypothesis, 236
simple hypothesis, 251
test of hypothesis, 275
treatment hypothesis, 283
two-tailed alternative hypothesis, 289

**identification**
batch number, 17
bin number, 21
biological marker, 22
check digit, 31
deidentify, 69
deductive identification, 67
direct identifier, 71
Id check digit, 119
identification, 119
identification number, 119
identify, 120
identity, 119
indirect identifier, 125
linkable data, 146
linkage, 146
linkage variable, 146
linked data, 146
lot number, 149
name code, 165
personal identifier, 193
probabilistic identification, 208
reidentify, 230
registration, 229
serial number, 248
study identification number, 264
unique identifier, 294

**inference**
fiducial inference, 96
statistical inference, 258

Ingelfinger FJ, 127

**institution**
commercial institutional review board, 40
institutional review board (IRB), 128, 135, 136
approved consent form, 10
assent, 10
central institutional review board, 29
coerced consent, 38
consent form, 50
consent process, 51
emergency use, 82
ethicist, 86

**Health Insurance Portability and Accountability Act (HIPAA)**
covered entity, 58
deidentified data, 69
limited dataset, 145

Health Insurance Portability and Accountability Act (HIPAA), 114

Hendershot RA, 31
Henneken CH, 21
Hill AB, 129
Hippocratic Oath, 113
Hoaglin DC, 302
institutional review board (IRB) (Continued)
ethics committee, 86
ethics review board (ERB), 86
exempt research, 87
expedited review, 88
Federal Common Rule, 95
federalwide assurance, 96
finder’s fee, 97
guinea pig, 111
Helsinki committee, 115
incentive, 121
incentive payment, 121
independent institutional review board, 123
institutional assurance, 128
involve, 135
local institutional review board, 146
Office for Human Research Protections (OHRP), 178
parent institutional review board, 187
prototype consent form, 213
renewal, 231
research, 235
research subject, 236

interval
class interval, 32
closed class interval, 36
closed interval, 37
confidence interval, 46
interval censoring, 132
interval data, 132
interval estimate, 132
open class interval, 179
open interval, 179

Jones JH, 88
Kaplan EL, 138
Karnegis JN, 76
Katz J, 113
Katz S, 2
Kefauver CE, 77, 138
Kendall MG, 139
Kennedy D, 77
Knuth DE, 213
Kuebler RR, 101
Kupelnick B, 101

label insert
black box warning, 23
Lachin JM, 296
Lakatos E, 269
Last JM, 12, 28, 48, 80, 84, 115, 207, 245, 274
Lau J, 101
Lellouch J, 90, 129, 151, 202
Leon AS, 76
Levine RJ, 19, 41, 68, 138, 236, 303
Lewis S, 101

life analysis
conditional life expectancy, 46
conditional survival rate, 46
health-related quality of life, 114
health-related quality of life measures, 114
life expectancy, 144
lifetable, 144
lifetable analysis, 144
quality of life, 217
quality of life indicator, 218
quality of life measure, 218
survival, 269
survival analysis, 269
survival curve, 269
survival probability, 269
survival rate, 269
unconditional life expectancy, 292

likelihood
likelihood, 144
likelihood function, 144
likelihood principle, 144
likelihood ratio, 144
maximum likelihood method, 154
minimum likelihood treatment assignment, 157
Likert R, 145

limit
alert limit, 6
central limit theorem, 30
central limit theorem of the mean, 30
confidence limits, 46
fiducial limits, 96
Kaplan–Meier product limit, 138
monitoring limit, 159
normal limit, 172
prediction limits, 203
tolerance limits, 277
Long JM, 76

Macular Photocoagulation Studies, 160
Mann HB, 151, 302
Mantel N, 28, 148, 151, 183

mask/masking
collateral unmasking, 40
collateral masking, 43
collateral masked, 44
data collection mask, 63
double mask, double masked, 75
double-mask, double-masked, 75
double-masked treatment, 75
en masse unmasking, 83
global unmasking, 108
mask, 152
mask, masked, 151
mask, masking, masks, 152
masked data analysis, 152
masked data collection, 152
masked randomization, 152
masked reading, 152
masked treater, 152
masked treatment, 152
masked treatment administration, 152
masked treatment assignment, 45, 152
masked treatment effects monitoring, 152
masked treatment effects monitoring committee, 152
masked treatment effects monitoring report, 152
masked trial, 153
masking level, 153
nonmask, 171
nonmask, nonmasked, 171
nonmasked treatment assignment, 171
nonmasked trial, 171
partial mask, 187
partially masked, 188
partially masked trial, 188
patient mask, 190
physician mask, 195
reader mask, 226
single masked, single mask, 252
single-mask, single-masked, 253
single-masked treatment, 253
treater mask, 279
treatment masking, 284
treatment result mask, 285
triple mask, 288
triple-mask, triple-masked, 288
triple-masked trial, 288
unmask, unmasked, 294
unmask, unmasked, unmasking, unmasks, 294
unmasked randomization, 295
unmasked treatment assignment, 295
unmasked treatment effects monitor, 295
unmasked treatment effects monitoring, 295
unmasked treatment effects monitoring committee, 295
unmasked treatment effects monitoring report, 295
unmasked trial, 295
unmasking bias, 295

**match/matching**

- category matching, 28
- frequency matching, 103
- group matching, 110
- individual matching, 125
- match, matched, matching, matches, 153
- matched control, 153
- matched pair, 153
- matching placebo, 153
- overmatch, 183
- pair matching, 185
- undermatch, undermatched, undermatching, undermatches, 293

Matts JP, 76
McCauley RF, 113
McPherson K, 183

**mean**

- arithmetic mean, 10
- average, 13
- central limit theorem of the mean, 30
- deviation from mean, 71
- harmonic mean, 114
- mean, 154
- mean absolute deviation, 154
- mean deviation, 154
- mean square, 154
- mean square error, 154
- population mean, 199
- regression to the mean, 230
- root-mean square error, 240
- sample mean, 242
- weighted mean, 302

**measure**

- binary outcome measure, 22
- central tendency measure, 30
- compliance measure, 45
- Cronbach’s alpha, 59
- data collection compliance measure, 63
- followup compliance measure, 99
- health-related quality of life measures, 114
- location measure, 146
- measurement bias, 154
- measurement error, 154
- measurement validity, 154
- outcome measure, 182
- primary outcome measure, 206
- protocol compliance measure, 212
- quality of life measure, 218
- repeated measures design, 231
- replicate measure, 231
- scalar measure, 243
- variation measure, 299

**medicine**

- allopathic medicine, 6
- complementary medicine, 42
- escape medicine, 85
- evidence-based medicine, 87
- homeopathic medicine, 116
- medical device, 154
- medical device class, 155
- medical device, class I, 155
- medical device, class II, 155
- medical device, class III, 155
- medical ethics, 155
- medical ethics, principles of, 155
- medical judgment, 156
- medical treatment, 156
- medical trial, 156
- MEDLINE, 156
- National Institutes of Health, 166
- patent medicine, 188
- personalized medicine, 193
mechanism (Continued)
  primary care, 205
  primary care center, 206
  rescue medicine, 235
  secondary care, 245
  secondary care center, 245
  standard care, 256
  standard of medical care, 257
  tertiary care, 274
  tertiary care center, 274
  treating physician, 279
Meier P, 138
Meinert CL, 8, 58
meta-analysis
  ad hoc meta-analysis, 2
  cumulative meta-analysis, 60
  designed meta-analysis, 70
  meta-analysis, 156
  network meta-analysis, 168
  overview, 183
  real-time meta-analysis, 226
Metz CE, 226
Michael M, 79
Miller RG, 137
model
  Cox proportional hazards regression model, 59
  fixed-effects model, 98
  generalized linear model, 108
  linear model, 145
  linear regression model, 145
  log-linear model, 147
  logistic regression model, 147
  logit model, 147
  mixed-effects model, 157
  model equation, 157
  multiple linear regression model, 162
  multiple logistic regression model, 162
  nonlinear model, 170
  nonlinear regression model, 170
  proportional hazards regression model, 211
  random-effects model, 222
  regression model, 230
  urn model, 296
  urn model randomization, 296
  urn model treatment assignment, 296
monitor
  administrative look, 4
  efficacy look, 81
  look restriction, 148
  safety look, 241
monitor/monitoring
  administrative review, 4
  advisory-review & trt effects monitoring
    committee (ARTEMIC), 5
  apartheid treatment effects monitoring, 9
  asymmetrical treatment effects monitoring, 12
  competency requirement, 42
  data and safety monitoring, 63
  data and safety monitoring committee (DSMC), 63
  data monitoring, 65
  data monitoring committee (DMC), 65
  data monitoring report, 65
  efficacy monitoring, 81
  efficacy review, 81
  external treatment effects monitoring committee, 91
  field monitor, 97
  interim look, 130
  interim review, 130
  internal treatment effects monitoring committee, 131
  masked treatment effects monitoring, 152
  masked treatment effects monitoring committee, 152
  masked treatment effects monitoring report, 152
  monitor, monitored, monitoring, monitors, 159
  monitoring committee, 159
  monitoring design, 159
  monitoring limit, 159
  objectivity requirement, 175
  patient monitoring, 190
  patient safety monitoring, 190
  performance monitoring, 191
  performance monitoring committee, 192
  performance monitoring report, 192
  performance review, 192
  protocol monitor, 212
  protocol monitoring, 212
  record monitor, 228
  record monitoring, 228
  safety monitoring, 241
  safety monitoring committee, 241
  safety review, 242
  study clinic monitor, 263
  symmetrical treatment effects monitoring, 270
  treatment effects and performance monitoring
    committee, 282
  treatment effects monitor, 282
  treatment effects monitoring, 282
  treatment effects monitoring and analysis
    committee, 282
  treatment effects monitoring committee (TEMIC), 282
  treatment effects monitoring report, 283
  unmasked treatment effects monitor, 295
  unmasked treatment effects monitoring, 295
  unmasked treatment effects monitoring
    committee, 295
  unmasked treatment effects monitoring report, 295
Mood AM, 296
Morganstern H, 239
Mosteller F, 101, 302
Multiple Risk Factor Intervention Trial, 163, 239
National Academy of Sciences, 77
National Center for Health Statistics (NCHS), 165
National Health and Nutrition Examination Survey (NHANES), 165
National Health Interview Survey (NHIS), 165
National Commission for Protection of Research Subjects, 137
National Commission for the Protection of Human Subjects, 18
National Death Index (NDI), 165
National Health and Nutrition Examination Survey (NHANES), 165
National Health Interview Survey (NHIS), 165
National Institutes of Health, 291
National Institutes of Health (NIH), 33, 53, 56, 91, 109, 133, 135, 163, 165, 166, 178, 190, 208, 210, 234, 235, 255, 265, 297
National Institutes of Health Revitalization Act of 1993, 166
National Research Council, 77
National Technical Information Service (NTIS), 166
Newcomb S, 19
Neyman J, 168
number
batch number, 17
identification number, Id number, 119
IND number, 123
law of large numbers, 141
lot number, 149
number adaptive randomization, 173
number needed to treat, 173
ordinal number, 181
pseudorandom number, 213
quasirandom number, 218
random number, 222
random number generator, 222
relative number, 231
serial number, 248
study identification number, 264
Nutton V, 113
O’Quigley J, 53
observation
baseline observation period, 17
correlated observations, 57
direct observation, 72
followup observation, 100
left censored observation, 143
observation control, 175
observation control treatment, 175
observation unit, 175
observation variable, 175
observational study, 175
paired observations, 185
right censored observation, 238
Occam’s razor, 176
odds
log-odds ratio, 147
odds, 177
posterior odds, 202
relative betting odds, 231
office
study officers, 264
Office for Human Research Protections (OHRP), 178
Office for Protection from Research Risks (OPRR), 87, 88, 135, 235, 236
Office of Research Integrity (ORI), 67, 178
Office of Research on Women’s Health (ORWH), 178
office/officer
contract office, 53
contract officer, 54
grants office, 110
grants officer, 110
Office for Human Research Protections (OHRP), 178
Office of Research Integrity (ORI), 178
office of the study chair, 178
officers of the study, 178
operations office, 180
program office, 210
program officer, 210
project office (PO), 210
project officer (PO), 210
study officer, 264
outcome
binary outcome, 21
binary outcome measure, 22
composite outcome, 45
endpoint, 83
hard outcome, 113
intermediate outcome, 131
multiple outcomes, 162
outcome, 182
outcome adaptive random treatment assignment, 182
outcome adaptive treatment assignment, 182
outcome event, 182
outcome measure, 182
outcome research, 182
outcome variable, 183
patient-centered outcomes research, 190
patient-reported outcome, 190
primary outcome, 206
primary outcome measure, 206
primary outcome variable, 207
secondary outcome, 245
secondary outcome measure, 245
soft outcome, 254
surrogate outcome, 269
surrogate outcome measure, 269
surrogate outcome variable, 269
two-armed bandit outcome adaptive assignment, 288
Packard FR, 35, 89
Paré A, 35, 89
parameter
alternative hypothesis, 7
Bayesian statistics, 18
biased, 20
biased estimator, 21
bivariate normal distribution, 23
bootstrap method, 25
composite hypothesis, 45
degree of freedom, 46
consistent estimator, 51
dimension, 71
distribution-free method, 73
error, 85
estimator, 86
expected value, 88
confidence interval, 96
Fisher’s Exact Test, 97
fixed-effects model, 98
generalized estimating equation, 108
generalized linear model, 108
jackknife method, 137
Kaplan–Meier product limit, 138
likelihood function, 144
likelihood ratio, 144
linear equation, 145
linear model, 145
linear regression analysis, 145
linear regression model, 145
location measure, 146
logistic regression model, 147
logrank test statistic, 148
Mann–Whitney test, 151
maximum likelihood method, 154
mean square error, 154
model equation, 157
moments, method of, 158
nonlinear equation, 170
nonlinear model, 170
nonlinear regression model, 170
parametric, 171
nuisance parameter, 172
one-tailed alternative hypothesis, 179
overparameterize, 183
parameter, 186
parametric, 186
parametric test, 187
Pearson product-moment correlation coefficient, 191
point estimate, 199
pooled estimate, 199
population mean, 199
population parameter, 200
power function, 202
random-effects model, 222
randomization test, 223
cal parameter, 243
sign test, 250
signed-rank test, 251
simple hypothesis, 251
two-tailed alternative hypothesis, 289
unbiased estimator, 292
uniformly most powerful test, 294
variance, 299
variance-covariance matrix, 299
Wilcoxon test, 302

patient/person
aggregate patient data, 6
aggregate patient data meta-analysis, 6
between-person study, 20
between-person trial, 20
case patient, 54
case-assigned patient, 54
case-treated patient, 55
direct patient contact, 72
direct patient recruitment, 72
evaluable study patient, 86
evaluable study patients, 86
final patient examination, 97
indirect patient contact, 125
indirect patient recruitment, 125
individual patient data, 126
individual patient data meta-analysis, 126
noncompliant person, 169
nonevaluable study patient, 170
parallel patient, 186
patient advocate, 188
patient close-out, 189
patient close-out examination, 189
patient compliance, 189
patient contact schedule, 189
patient enrollment, 189
patient enrollment period, 189
patient examination, 189
patient followup, 189
patient followup close-out design, 189
patient information booklet, 189
patient mask, 190
patient monitoring, 190
patient population, 190
patient safety monitoring, 190
patient treatment compliance, 190
patient-centered outcomes research, 190
patient-centered outcomes research, 190
person-time, 192
person-year, 192
placebo patient, 196
placebo-assigned patient, 197
placebo-treated patient, 198
prospective person-time, 211
respect for persons, principle of, 236
retrospective person-time, 237
retrospective person-year, 237
start-up patient, 258
study patient, 264
test patient, 275
test-assigned patient, 276
placebo-assigned group, 197
placebo-assigned patient, 197
placebo-control treatment, 197
placebo-controlled trial, 197
placebo-treated, 197
placebo-treated group, 198
placebo-treated patient, 198
single placebo, 252
single placebo treatment design, 252
therapeutic placebo, 276

Pearce MB, 76
Pearson ES, 168
Pearson K, 191
Pepe M, 53

period
baseline observation period, 17
baseline period, 17
edit period, 79
followup period, 100
funding period, 104
latent period, 141
lead-in period, 142
multi-period crossover treatment design, 160
n-period crossover design, 165
patient enrollment period, 189
placebo lead-in period, 196
placebo period, 196
post-treatment followup period, 201
run-in period, 240
shakedown period, 249
titration period, 277
treatment and followup period, 279
treatment period, 284
two-period crossover design, 289
washout period, 301

Peto J, 148, 183
Peto R, 148, 183
Physicians' Desk Reference, 195
Physicians' Health Study, 21, 163, 252
Pike MC, 183
Pines WL, 193, 194

placebo
double placebo treatment design, 75
matching placebo, 153
multiple placebo, 162
multiple placebo treatment design, 163
placebo, 195, 196
placebo control, 196
placebo effect, 196
placebo group, 196
placebo lead-in period, 196
placebo patient, 196
placebo period, 196
placebo reactor, 197
placebo response, 197
placebo treatment, 197
placebo treatment effect, 197
placebo washout, 197
placebo-assigned, 197

Pocock SJ, 111, 129, 157
Poisson SD, 199

population
base population, 16
dynamic population, 78
open population, 180
parent population, 187
patient population, 190
population controls, 199
population frame, 199
population mean, 199
population parameter, 200
population-based trial, 200
reference population, 229
standard population, 257
study population, 265
target population, 273
POSCH Group, 76

position
appointed study chair, 10
circuit rider, 32
co-investigator, 38
co-principal investigator, 38
current principal investigator, 53
coordinator, 57
data coordinator, 64
elected study chair, 82
fiat study chair, 96
field monitor, 97
investigator, 134
investigator IND, 134
investigator of record, 135

PI representation construct, 195
principal investigator (PI), 208
program director, 210
protocol monitor, 212
rotating study chair, 240
study center director, 262
study chair, 262
study chair external, 262
study chair internal, 263
study clinic coordinator, 263
study clinic director, 263
study clinic monitor, 263
**position** (Continued)
study coordinator, 263
study investigator, 264
study officer, 264
study principal investigator, 265
study vice-chair, 266
unmasked treatment effects monitor, 295

**power**
conditional power, 46
expected power, 88
observed power, 176
power, 202
power function, 202
uniformly most powerful test, 294
Prentice RL, 28, 269

**probability**
a priori probability, 1
alpha error, 6
Bayes’ theorem, 18
binomial distribution, 22
bivariate density function, 23
bivariate distribution, 23
bivariate normal distribution, 23
chi-square distribution, 31
conditional probability, 46
joint probability function, 137
likelihood, 144
likelihood function, 144
likelihood principle, 144
likelihood ratio, 144
maximum likelihood method, 154
minimum likelihood treatment assignment, 157
posterior probability, 202
probability, 208
probability density, 209
probability density function, 209
probability distribution function (pdf), 209
probability mass, 209
probability mass function, 209
probability sample, 209
survival probability, 269
treatment assignment probability, 280
type I error, 289
type II error, 289
unconditional probability, 292

**procedure**
adjustment procedure, 4
sham procedure, 249

**proposal**
contract proposal, 54
funding proposal, 104
grant proposal, 110
investigator-initiated research proposal, 135
noncompetitive proposal, 169
request for proposal (RFP), 234
research contract proposal, 235
research grant proposal, 236
research proposal, 236
sponsor-initiated research proposal, 255

**protocol**
amended protocol, 7
approved protocol, 10
approved protocol change, 10
common study protocol, 41
data collection protocol, 64
elective study protocol, 82
elective study protocol construct, 82
elective study protocol multi-study network, 82
multicenter study protocol, 161
multiprotocol study, 163
off-protocol, 177
on-protocol, 178
per protocol analysis, 191
protocol, 211
protocol amendment, 211
protocol bailout, 212
protocol change, 212
protocol compliance, 212
protocol compliance measure, 212
protocol departure, 212
protocol development stage, 212
protocol deviation, 212
protocol exemption, 212
protocol infraction, 212
protocol monitor, 212
protocol monitoring, 212
protocol override, 212
protocol suspension, 213
protocol violation, 213
salvage protocol, 242
single-center study protocol, 252
stepped treatment protocol, 259
study protocol, 265
subprotocol, 268
treatment protocol, 285
treatment protocol suspension, 285
treatment protocol violation, 285
trial protocol, 288

**publication**
ancillary publication, 8
baseline results paper, 17
clinical alert, 35
design and methods paper, 70
design, methods, and baseline results paper, 70
interim publication, 130
primary publication, 207
publication, 214
publication bias, 214
publication committee, 214
publication type, 214
results paper, 237
secondary publication, 245
Vancouver Convention, 298

**quantile**
centile, 29
<table>
<thead>
<tr>
<th>Term</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>fractile</td>
<td>102</td>
</tr>
<tr>
<td>interquartile range</td>
<td>132</td>
</tr>
<tr>
<td>mid-quartile</td>
<td>156</td>
</tr>
<tr>
<td>percentile</td>
<td>191</td>
</tr>
<tr>
<td>quantile</td>
<td>218</td>
</tr>
<tr>
<td>quartile</td>
<td>218</td>
</tr>
<tr>
<td>quintile</td>
<td>219</td>
</tr>
<tr>
<td>tercile</td>
<td>273</td>
</tr>
<tr>
<td>Quetelet LAJ</td>
<td>219</td>
</tr>
</tbody>
</table>

**random/randomized**

- Bernoulli random variable, 19
- dependent random variable, 69
- independent random variable, 123
- lognormal random variable, 148
- nonrandom, 171
- nonrandomized, 171
- nonrandomized trial, 171
- normal random variable, 172
- outcome adaptive random treatment assignment, 182
- pseudorandom, 213
- pseudorandom number, 213
- pseudorandom process, 213
- quasirandom, 218
- quasirandom number, 218
- random, 221
- random assignment, 221
- random censoring, 221
- random digit dialing, 221
- random effect, 221
- random error, 221
- random number, 222
- random number generator, 222
- random order, 222
- random permutation, 222
- random sample, 222
- random sampling, 222
- random start, 222
- random treatment assignment, 222
- random variable, 222
- random variation, 222
- random-effects model, 222
- randomized, 223
- randomized block, 223
- randomized block design, 223
- randomized clinical trial (RCT), 223
- randomized control, 223
- randomized control trial (RCT), 223
- randomized controlled trial (RCT), 224
- randomized response technique, 224
- randomized trial, 224
- randomly selected control, 224
- randomness, 224
- randomness test, 225
- simple random sample, 251
- standardized random variable, 257
- stratified random sample, 261
- stratified random sampling, 261
- stratified random treatment assignment, 261
- systematic random sample, 270
- unrestricted random assignment, 295

**randomization**

- balanced randomization list, 15
- blocked randomization, 25
- complete randomization, 43
- fixed randomization design, 98
- group randomization, 110
- haphazardization, 113
- masked randomization, 152
- number adaptive randomization, 173
- prerandomization examination, 204
- randomization, 222
- randomization breakdown, 223
- randomization design, 223
- randomization test, 223
- randomization unit, 223
- restricted randomization, 237
- stratified randomization, 261
- stratified-blocked randomization, 261
- treatment assignment, see also, 279
- unmasked randomization, 295
- urn model randomization, 296

**rate**

- adjusted mortality rate, 3
- attack rate, 12
- clearance rate, 32
- conditional survival rate, 46
- crude mortality rate, 60
- crude rate, 60
- direct rate adjustment, 72
- event rate, 87
- hazard rate, 114
- incidence rate, 122
- indirect rate adjustment, 125
- instantaneous rate, 128
- morbidity rate, 159
- mortality rate, 160
- observed rate, 176
- prevalence rate, 205
- proportionate mortality rate (PMR), 211
- rate, 225
- rate adjustment, 225
- standardized rate, 258
- survival rate, 269

**ratio**

- cost–benefit ratio, 58
- expected assignment ratio, 88
- fixed treatment assignment ratio, 98
- likelihood ratio, 144
- log-odds ratio, 147
- observed treatment assignment ratio, 176
- ratio, 225
- ratio estimate, 225
- risk–benefit ratio, 240
- specified assignment ratio, 255
ratio (Continued)
standardized morbidity ratio, 257
standardized mortality ratio (SMR), 257
treatment assignment ratio, 280
uniform treatment assignment ratio, 294
variance ratio, 299
record
case record, 27
data record, 66
on-site record audit, 179
original record, 182
primary record, 207
record audit, 227
record auditor, 227
record linkage, 228
record monitor, 228
record monitoring, 228
source record, 254
vital records, 300
recruitment
direct patient recruitment, 72
enrollment, see also, 83
indirect patient recruitment, 125
recruitment and enrollment stage, 228
recruitment log, 228
region
acceptance region, 1
critical region, 59
rejection region, 230
regression
backward elimination, 15
backward stepwise regression, 15
Cox proportional hazards regression model, 59
forward selection, 101
forward stepwise regression, 101
linear regression, 145
linear regression analysis, 145
linear regression model, 145
logistic regression, 147
logistic regression model, 147
multiple linear regression, 162
multiple linear regression analysis, 162
multiple linear regression model, 162
multiple logistic regression, 162
multiple logistic regression analysis, 162
multiple logistic regression model, 162
multiple regression, 163
nonlinear regression model, 170
proportional hazards regression model, 211
regression, 229
regression analysis, 229
regression coefficient, 229
regression curve, 229
regression dilution bias, 229
regression equation, 229
regression estimate, 230
regression line, 230
regression model, 230
regression to the mean, 230
simultaneous regression, 252
stepwise regression, 259
Reitman D, 223
report
case report, 27
case report form, 27
data monitoring report, 65
performance monitoring report, 192
progress report, 210
safety report, 242
treatment effects monitoring report, 283
research
clinical research associate, 34
comparative effectiveness research, 41
contract research organization (CRO), 54
cooperative research and development agreement (CRADA), 56
exempt research, 87
extramural research, 91
indirect research cost, 125
intramural research, 133
investigator-initiated research proposal, 135
Office for Human Research Protections (OHRP), 178
Office of Research Integrity (ORI), 178
Office of Research on Women’s Health (ORWH), 178
operations research, operational research, 181
outcome research, 182
patient-centered outcomes research, 190
research, 235
research application, 235
research contract proposal, 235
research grant, 235
research grant application, 235
research grant proposal, 236
research group, 236
research hypothesis, 236
research misconduct, 236
research program, 236
research project, 236
research proposal, 236
research subject, 236
sponsor-initiated research proposal, 255
translational research, 278
result
ancillary result, 8
dredged result, 75
final treatment result, 97
informative null result, 126
interim result, 130
interim treatment result, 130
negative result, 167
null result, 172
positive result, 200
primary result, 207
results blackout, 237
secondary result, 246
test result, 275
treatment result, 285
treatment result mask, 285
uninformative null result, 294

review
advisory-review & trt effects monitoring committee (ARTEMC), 5
advisory-review committee (ARC), 5
central institutional review board, 29
commercial institutional review board, 40
editorial review committee, 80
ethics review board (ERB), 86
expedited review, 88
external advisory committee (EAC), 91
independent institutional review board, 123
institutional animal care and use committee (IACUC), 128
institutional review board (IRB), 128
institutional review board approval, 135
institutional review board approval renewal, 136
institutional review board of record, 136
local institutional review board, 146
overview, 183
parent institutional review board, 187
review group, 238
study review visit, 265
systematic review, 270

right
autonomy, right of, 12
investigator right, 135
primacy, right of, 205
refusal, right of, 229
study subject right, 266
subject right, 266
withdrawal, right of, 303
withdrawal, right of, 303

risk
absolute risk reduction, 1
attributable risk, 12
competing risk, 42
minimal risk, 156
more than minimal risk, 159
relative risk, 231
relative risk reduction, 231
risk, 239
risk assessment, 239
risk concentration, 239
risk concentration design, 239
risk factor, 239
risk factor analysis, 239
risk profile, 239
risk profile analysis, 240
risk-benefit analysis, 240
risk-benefit ratio, 240
teratogenic risk classification of approved drugs, 78

Robbins H, 198
Robertson JA, 68

Robin ED, 113
Rothman KJ, 28
Royall RM, 41

rule
analysis rule, 240
counting rule, 58
Ingelfinger rule, 127
stopping rule, 260

Sackett DL, 90, 129, 151, 202

sample size
achieved sample size, 2
calculated sample size, 27
effective sample size, 80
enrollment goal, 84
enrollment quota, 84
estimated sample size, 86
expected effective sample size, 88
expected sample size, 88
fixed sample size, 98
fixed sample size design, 98
jack-up factor, 137
observed effective sample size, 176
observed sample size, 176
patient enrollment goal, 189
patient enrollment quota, 189
pragmatic sample size, 202
sample size, 242
sample size calculation, 242
sample size design, 242
sample size of convenience, 242
sequential sample size design, 248

sample/sampling
bootstrap sample, 25
cluster sample, 37
cluster sampling, 37
convenience sample, 56
independent sample, 124
paired sample, 185
population frame, 199
probability sample, 209
quota sample, 219
quota sampling, 219
random sample, 222
random sampling, 222
representative sample, 234
representative sampling, 234
sample, 242
sample mean, 242
sample variance, 242
sampling design, 242
sampling distribution, 242
sampling frame, 243
sampling unit, 243
sampling variation, 243
sampling with replacement, 243
sampling without replacement, 243
simple random sample, 251
sample/sampling (Continued)
  stratified random sample, 261
  stratified random sampling, 261
  systematic random sample, 270
  systematic sample, 270
  systematic sampling, 271
Sanmarco ME, 76
Savage IR, 148
Sawin HS, 76
scale
  Likert scale, 145
  scalar measure, 243
  scalar parameter, 243
  visual analogue scale, 300
Schlesselman JJ, 28
Schoolmaker RC, 31
Schroeder B, 223
Schwartz D, 90, 129, 151, 202
Selmer ES, 31
Shapiro S, 32, 60
side effect
  adverse drug experience, 4
  adverse side effect, 5
  safety report, 242
  serious adverse drug experience, 249
  side effect, 250
  toxic side effect, 278
  treatment side effect, 285
  unexpected adverse drug experience, 293
significant/significance
  clinical significance, 34
  clinically significant, 36
  significance level, 251
  significant difference, 251
  significant digit, 251
  significant other, 251
  statistical significance, 258
  test of significance, 275
Silverman B, 223
Simon R, 2
site
  data collection site, 64
  data generation site, 65
  off-site audit, 177
  on-site audit, 179
  on-site record audit, 179
  parent site, 187
  reverse study site visit, 238
  site visit, 253
  study site, 265
  study site visit, 265
  treatment site, 285
Smink Jr RD, 76
Smith H, 101
Smith H Jr, 223
Smith PG, 183
Smythe M, 31
Society for Clinical Trials (SCT), 254
stage of trial
  close-out stage, 36
  design and funding stage, 70
  design stage, 70
  followup stage, 100
  funding stage, 104
  post-trial followup stage, 202
  protocol development stage, 212
  recruitment and enrollment stage, 228
  termination stage, 274
  treatment and followup stage, 279
start-up
  clinic start-up design, 33
  start-up design, 258
  start-up patient, 258
  start-up stage, 258
  test patient, 275
  trial start-up design, 288
  vanguard patients, 299
Stevenson JW, 76
stratify
  multiple stratification, 163
  overstratify, 183
  post-stratification, 201
  post-stratify, 201
  principal stratification, 208
  stratification, 260
  stratification variable, 261
  stratified random sample, 261
  stratified random sampling, 261
  stratified random treatment assignment, 261
  stratified randomization, 261
  stratified treatment assignment, 261
  stratified-blocked randomization, 261
  stratify, 262
  stratum, 262
study
  adaptive study design, 2
  ancillary study, 8
  appointed study chair, 10
  auxiliary study, 13
  baseline study, 17
  before and after study, 18
  between-person study, 20
  bioavailability study, 22
  case study, 28
  case—cohort study, 28
  case—cohort study design, 28
  case—control study, 28
  case—control study design, 28
  challenge study, 31
  clearance study, 32
  clinic study roll, 33
  cohort study, 39
  collaborative study, 40
  common study protocol, 41
  comparative study, 41
  concurrent cohort study, 45
concurrent followup study, 45

cross-sectional study, 59
daughter study, 67
dose ranging study, 74
Drug Efficacy Study (DES), 77
Drug Efficacy Study Implementation (DESI), 77
ecological study, 79
elected study chair, 82
elective study protocol, 82
elective study protocol construct, 82
elective study protocol multi-study network, 82
epidemiological study, 84
evaluative study patients, 86
external study validity, 91
fiat study chair, 96
fixed study design, 98
follow-on study, 99
followup study, 100
internal study validity, 131
intervention study, 132
key study document, 139
long-term study, 148
main study, 151
multi-study, 160
multi-study design, 160
multi-study network, 160
multi-study structure, 160
multicenter study, 161
multicenter study protocol, 161
multinational study, 161
multiprotocol study, 163
natural history study, 166
negative study, 167
nested case-control study, 168
nonconcurrent cohort study, 169
nonconcurrent followup study, 170
nonconcurrent prospective study, 170
nonexperimental study, 170
observational study, 175
off-study, 177
officers of the study, 178
on-study, 179
paperless study, 186
parallel study, 186
parent study, 187
pilot study, 195
positive study, 200
prospective followup study, 211
representative study population, 234
retrospective followup study, 237
retrospective study, 238
reverse study site visit, 238
rotating study chair, 240
salvage study, 242
short-term study, 250
single-center study, 252
single-center study protocol, 252
sister study, 253
study, 262
study candidate, 262
study center, 262
study center director, 262
study chair, 262
study chair external, 262
study chair internal, 263
study clinic, 263
study clinic coordinator, 263
study clinic director, 263
study clinic monitor, 263
study close-down, 263
study committee, 263
study coordinator, 263
study credit roster, 263
study data, 263
study database, 263
study design, 263
study directory, 263
study document, 263
study group, 264
study handbook, 264
study home visit, 264
study identification number, 264
study investigator, 264
study manual, 264
study manual of operations, 264
study manuscript, 264
study name, 264
study network, 264
study officer, 264
study participant, 264
study patient, 264
study population, 265
study presentation, 265
study principal investigator, 265
study protocol, 265
study re-entry, 265
study result, 265
study review visit, 265
study roll, 265
study section, 265
study site, 265
study site visit, 265
study subject, 266
study treatment, 266
study treatment group, 266
study validity, 266
study vice-chair, 266
study visit, 266
study-treated, 266
study-treated group, 266
substray, 268
substray name, 268
transition study visit, 278
Tuskegee Study, 88
umbrella study name, 291
washout study visit, 301
**Study (Continued)**

within-person study, 303

**Study Index**

<table>
<thead>
<tr>
<th>Study</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain Resuscitation Clinical Trial II</td>
<td>68</td>
</tr>
<tr>
<td>Cardiac Arrhythmia Suppression Trial</td>
<td>142</td>
</tr>
<tr>
<td>Coronary Artery Surgery Study</td>
<td>262</td>
</tr>
<tr>
<td>Coronary Drug Project, 21, 43, 142, 161, 185, 196, 210, 252, 255</td>
<td></td>
</tr>
<tr>
<td>Diabetic Retinopathy Study</td>
<td>109</td>
</tr>
<tr>
<td>Drug Efficacy Study (DES)</td>
<td>77</td>
</tr>
<tr>
<td>Drug Efficacy Study Implementation (DESI)</td>
<td>77</td>
</tr>
<tr>
<td>Glaucoma Laser Trial</td>
<td>109, 185</td>
</tr>
<tr>
<td>Macular Photocoagulation Studies</td>
<td>160</td>
</tr>
<tr>
<td>Multiple Risk Factor Intervention Trial</td>
<td>163, 239</td>
</tr>
<tr>
<td>National Health and Nutrition Examination Survey (NHANES)</td>
<td>165</td>
</tr>
<tr>
<td>National Health Interview Survey (NHIS)</td>
<td>165</td>
</tr>
<tr>
<td>Physicians' Health Study, 21, 163, 252</td>
<td></td>
</tr>
<tr>
<td>Systolic Hypertension in the Elderly Program</td>
<td>109</td>
</tr>
<tr>
<td>Tuskegee Study</td>
<td>88</td>
</tr>
<tr>
<td>University Group Diabetes Program, 39, 75, 103, 163, 196, 200, 210</td>
<td></td>
</tr>
</tbody>
</table>

Sunter A, 31

Systolic Hypertension in the Elderly Program, 109

table

<table>
<thead>
<tr>
<th>Table Type</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>contingency table</td>
<td>53</td>
</tr>
<tr>
<td>dummy table</td>
<td>78</td>
</tr>
<tr>
<td>frequency table</td>
<td>103</td>
</tr>
<tr>
<td>lifetable</td>
<td>144</td>
</tr>
<tr>
<td>mock table</td>
<td>157</td>
</tr>
<tr>
<td>table shell</td>
<td>273</td>
</tr>
<tr>
<td>two-by-two table</td>
<td>289</td>
</tr>
<tr>
<td>two-way table</td>
<td>289</td>
</tr>
</tbody>
</table>

Taves DR, 157

Teratology Society, 78

test

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>chi-square test statistic</td>
<td>31</td>
</tr>
<tr>
<td>F test statistic</td>
<td>93</td>
</tr>
<tr>
<td>Fisher's Exact Test</td>
<td>97</td>
</tr>
<tr>
<td>goodness of fit test</td>
<td>109</td>
</tr>
<tr>
<td>logrank test statistic</td>
<td>148</td>
</tr>
<tr>
<td>Mann–Whitney test</td>
<td>151</td>
</tr>
<tr>
<td>Mantel–Haenszel test statistic</td>
<td>151</td>
</tr>
<tr>
<td>one-tailed test</td>
<td>179</td>
</tr>
<tr>
<td>parametric test</td>
<td>187</td>
</tr>
<tr>
<td>pilot test</td>
<td>195</td>
</tr>
<tr>
<td>positive predictive value of a test</td>
<td>200</td>
</tr>
<tr>
<td>pretest</td>
<td>204</td>
</tr>
<tr>
<td>randomization test</td>
<td>223</td>
</tr>
<tr>
<td>randomness test</td>
<td>225</td>
</tr>
<tr>
<td>sign test</td>
<td>250</td>
</tr>
<tr>
<td>signed-rank test</td>
<td>251</td>
</tr>
<tr>
<td>t test</td>
<td>273</td>
</tr>
<tr>
<td>test</td>
<td>274</td>
</tr>
<tr>
<td>test for randomness</td>
<td>274</td>
</tr>
<tr>
<td>test group</td>
<td>274</td>
</tr>
<tr>
<td>test of hypothesis</td>
<td>275</td>
</tr>
</tbody>
</table>

test of significance, 275

test patient, 275

test result, 275

test run, 275

test statistic, 275

test treatment, 275

test validity, 275

test-assigned, 275

test-assigned group, 276

test-assigned patient, 276

test-control treatment comparison, 276

test-control treatment difference, 276

test-treated, 276

test-treated group, 276

test-treated patient, 276

trend test, 287
	wo-tailed test, 289

uniformly most powerful test, 294

Wilcoxon test, 302

Z test, 305

**Theorem**

Bayes' theorem, 18

binomial theorem, 22

central limit theorem, 30

central limit theorem of the mean, 30

Tonascia S, 8, 58

treatment

<table>
<thead>
<tr>
<th>Treatment Type</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>a posteriori treatment comparison</td>
<td>1</td>
</tr>
<tr>
<td>a priori treatment comparison</td>
<td>1</td>
</tr>
<tr>
<td>active control treatment</td>
<td>2</td>
</tr>
<tr>
<td>active treatment</td>
<td>2</td>
</tr>
<tr>
<td>adjunctive treatment</td>
<td>3</td>
</tr>
<tr>
<td>adjuvant treatment</td>
<td>4</td>
</tr>
<tr>
<td>administered treatment</td>
<td>4</td>
</tr>
<tr>
<td>alternative treatment</td>
<td>7</td>
</tr>
<tr>
<td>analysis by administered treatment</td>
<td>7</td>
</tr>
<tr>
<td>analysis by assigned treatment</td>
<td>7</td>
</tr>
<tr>
<td>analysis by level of treatment adherence</td>
<td>7</td>
</tr>
<tr>
<td>apartheid treatment effects monitoring</td>
<td>9</td>
</tr>
<tr>
<td>assigned to treatment</td>
<td>11</td>
</tr>
<tr>
<td>assigned treatment</td>
<td>11</td>
</tr>
<tr>
<td>background treatment</td>
<td>15</td>
</tr>
<tr>
<td>best medical judgment control treatment</td>
<td>19</td>
</tr>
<tr>
<td>cold turkey treatment withdrawal</td>
<td>40</td>
</tr>
<tr>
<td>comparator treatment</td>
<td>41</td>
</tr>
<tr>
<td>comparison treatment</td>
<td>41</td>
</tr>
<tr>
<td>complex treatment</td>
<td>44</td>
</tr>
<tr>
<td>control treatment</td>
<td>54</td>
</tr>
<tr>
<td>crossed treatments</td>
<td>59</td>
</tr>
<tr>
<td>crossover treatment</td>
<td>60</td>
</tr>
<tr>
<td>crossover treatment structure</td>
<td>60</td>
</tr>
<tr>
<td>designed treatment comparison</td>
<td>70</td>
</tr>
<tr>
<td>direct treatment assignment system</td>
<td>72</td>
</tr>
<tr>
<td>direct treatment comparison</td>
<td>72</td>
</tr>
<tr>
<td>double-masked treatment</td>
<td>75</td>
</tr>
<tr>
<td>effective treatment</td>
<td>80</td>
</tr>
<tr>
<td>elective treatment</td>
<td>82</td>
</tr>
<tr>
<td>experimental treatment</td>
<td>89</td>
</tr>
</tbody>
</table>
treatment (Continued)
treatment trial, 286
treatment unit, 286
treatment variable, 286
treatment withdrawal, 286
treatment withdrawal trial, 286
treatment-related analysis bias, 286
treatment-related bias, 286
treatment-related feedback bias, 286
treatment-related followup bias, 287
treatment-related selection bias, 287
uncrossed treatments, 293
wait-list control treatment, 301
within-person treatment comparison, 303
treatment assignment
alternation treatment assignment, 7
assigned to treatment, 11
assigned treatment, 11
balanced incomplete treatment assignment block design, 15
baseline adaptive treatment assignment, 16
bias free treatment assignment, 20
biased coin treatment assignment, 20
bin number drug system, 21
blocked treatment assignments, 25
complete treatment assignment block, 43
complete treatment assignment block design, 43
controlled treatment assignment, 56
direct treatment assignment system, 72
envelope treatment assignment, 84
equal treatment assignment, 85
fixed randomization design, 98
fixed treatment assignment, 98
fixed treatment assignment design, 98
fixed treatment assignment ratio, 98
fixed treatment assignment schedule, 98
group randomization, 110
group treatment assignment, 111
haphazard treatment assignment, 113
imbalance minimization treatment assignment, 120
incomplete treatment assignment block design, 123
indirect treatment assignment system, 125
masked treatment assignment, 45, 152
med Id number drug system, 154
minimum likelihood treatment assignment, 157
nonmasked treatment assignment, 171
nonuniform treatment assignment, 172
observed treatment assignment ratio, 176
odd–even method of treatment assignment, 176
open treatment assignment, 180
outcome adaptive random treatment assignment, 182
outcome adaptive treatment assignment, 182
play-the-winner treatment assignment, 198
random treatment assignment, 222
randomization design, 223
randomization, see also, 222
restricted treatment assignment schedule, 237
simple treatment assignment, 251
stratified random treatment assignment, 261
stratified treatment assignment, 261
systematic treatment assignment, 271
treatment assignment, 279
treatment assignment bias, 280
treatment assignment block, 280
treatment assignment block effect, 280
treatment assignment block size, 280
treatment assignment design, 280
treatment assignment probability, 280
treatment assignment ratio, 280
treatment assignment unit, 280
treatment identification system, 283
uncontrolled treatment assignment, 292
uniform treatment assignment, 294
uniform treatment assignment ratio, 294
unit treatment assignment, 294
unmasked treatment assignment, 295
unrestricted treatment assignment, 295
unrestricted treatment assignment schedule, 295
urn model treatment assignment, 296
treatment crossover
complete treatment crossover, 43
treatment crossover, 281
treatment crossover trial, 281
treatment design
balanced treatment design, 15
block treatment design, 24
clinic preference treatment design, 33
complete block treatment design, 42
complete crossover treatment design, 43
complete factorial treatment design, 43
complex treatment design, 44
crossed treatment design, 59
crossover treatment design, 60
double placebo treatment design, 75
factorial treatment design, 94
Greco-Latin square treatment design, 110
incomplete block treatment design, 122
incomplete crossover treatment design, 122
incomplete factorial treatment design, 122
Latin square treatment design, 141
multi-period crossover treatment design, 160
multiple placebo treatment design, 163
paired treatment design, 185
parallel treatment design, 186
patient preference treatment design, 190
permuted block treatment design, 192
physician preference treatment design, 195
preference treatment design, 203
simple treatment design, 251
single placebo treatment design, 252
treatment design, 281
treatment effect
advisory-review & trt effects monitoring committee (ARTEMC), 5
antagonistic treatment effect, 9
asymmetrical treatment effects monitoring, 12
beneficial treatment effect, 19
internal treatment effects monitoring committee, 91
masked treatment effects monitoring, 152
masked treatment effects monitoring committee, 152
masked treatment effects monitoring report, 152
negative treatment effect, 167
net treatment effect, 168
nil treatment effect, 169
observed treatment effect, 176
placebo treatment effect, 197
positive treatment effect, 201
symmetrical treatment effects monitoring, 270
synergistic treatment effect, 270
treatment effect, 282
treatment effects and performance monitoring committee, 282
treatment effects monitor, 282
treatment effects monitoring, 282
treatment effects monitoring and analysis committee, 282
treatment effects monitoring committee (TEMC), 282
treatment effects monitoring report, 283
unmasked treatment effects monitor, 295
unmasked treatment effects monitoring, 295
unmasked treatment effects monitoring committee, 295
unmasked treatment effects monitoring report, 295
crossover trial, 60
data simple trial, 66
definitive trial, 68
demonstration trial, 69
device trial, 71
diagnostic trial, 71
effectiveness trial, 80
efficacy trial, 81
end of trial, 83
equivalence trial, 85
experimental trial, 89
exploratory trial, 90
feasibility trial, 95
field trial, 97
full-scale trial, 104
IND trial, 123
inferiority trial, 126
intervention trial, 132
licensure trial, 144
maintenance trial, 151
management trial, 151
masked trial, 153
medical trial, 156
Monte Carlo trial, 159
morphed trial, 160
multi-trial, 160
multi-trial design, 160
multi-trial structure, 160
multicenter trial, 161
multidisciplinary trial, 161
n of 1 trial, 165
natural trial, 166
noninferiority trial, 170
nonmasked trial, 171
nonrandomized trial, 171
open label trial, 180
open sequential trial, 180
open trial, 180
partially masked trial, 188
phase I drug trial, 193
phase I trial, 193
phase II/III drug trial, 193
phase II/III trial, 193
phase II drug trial, 193
phase II trial, 193
phase II/III drug trial, 193
phase II/III trial, 193
phase III drug trial, 194
phase III trial, 194
phase IV drug trial, 194
phase IV trial, 194
pilot trial, 195
pivotal trial, 195
placebo-controlled trial, 197
population-based trial, 200
post-trial followup, 201
post-trial followup stage, 202

trial
adequate and well-controlled trial, 3
Bernoulli trial, 19
between-person trial, 20
big and data simple trial, 21
big trial, 21
class of trial, 32
clinical trial, 34
clinical trial authorization, 35
clinical trial certificate, 35
clinical trial exemption certificate, 35
Clinical Trials Directive, 35
clinically directive trial, 35
close of trial, 36
Cochrane Central Register of Controlled Trials, 38
collaborative trial, 40
community trial, 41
completed trial, 44
complex trial, 44
Consolidated Standards of Reporting Trials, 51
Consolidated Standards of Reporting Trials (CONSORT), 302
controlled clinical trial, 55
controlled trial, 56
trial (Continued)
post-trial followup visit, 202
pragmatic trial, 202
preclinical trial, 203
preliminary trial, 204
prevention trial, 205
primary prevention trial, 207
prophylactic trial, 210
randomized clinical trial (RCT), 223
randomized control trial (RCT), 223
randomized controlled trial (RCT), 224
randomized trial, 224
registration trial, 229
reporting trials, 51
safety trial, 242
secondary prevention trial, 245
sequential trial, 248
short-term trial, 250
simple trial, 251
single-center trial, 252
Society for Clinical Trials (SCT), 254
stage of trial, 256
stopped trial, 260
strategy trial, 260
superiority trial, 268
therapeutic trial, 276
translational trial, 278
treatment crossover trial, 281
treatment trial, 286
treatment withdrawal trial, 286
trial, 287
trial and error, 287
trial close-out design, 287
trial completer, 288
trial proper, 288
trial start-up design, 288
trial stop, 288
trial termination, 288
trial-proper, 288
trial-proper patient, 288
triple-masked trial, 288
type of trial, 289
uncontrolled clinical trial, 292
uncontrolled trial, 292
unmasked trial, 295
vaccine trial, 297
within person trial, 303
within-person trial, 303
Tukey JW, 302
Tuna N, 76
Tuskegee Study, 88

University Group Diabetes Program, 39, 75, 103, 163, 196, 200, 210
University Group Diabetes Program Research Group, 39, 75, 200

usage note
academic trial, 1
adaptive study design, 2
adherence, 3
adjudicated reading, 3
adjunctive treatment, 3
administrative review, 4
adverse event, 5
adverse reaction, 5
age, 5
aggregate data, 6
allocation, 6
analysis by assigned treatment, 7
analysis by intention to treat, 7
ancillary study, 8
anonymous data, 9
apartheid treatment effects monitoring, 9
applied research, 9
archive, 10
assent, 10
assent, assented, assenting, assents, 10
assignment, 11
association, 11
asymmetrical treatment effects monitoring, 12
attributable risk, 12
author, 12
authorship credit, 12
average, 13
balanced, 15
bank, 15
baseline, 16
baseline data, 16
baseline period, 17
baseline study, 17
baseline visit, 17
basic research, 17
before and after study, 18
bi-, 20
bias, 20
big and data simple trial, 21
big trial, 21
blind, 24
block, 24
careful, 27
causal relationship, 28, 230
cause and effect, 28
censor, censored, censoring, censors, 28
center, 29
circadian, 32
clinical, 33
clinical equipoise, 34
clinical investigation, 34
clinical trial, 34
close of trial, 36

United States Congress, 166, 178, 297
Health Insurance Portability and Accountability Act, 114
United States Public Health Service (USPHS), 100, 128, 165
cluster, 37
cor-, 37
co-enrollment, 37
co-principal, 38
co-principal investigator, 38
coerced consent, 38
cohort, 39
cohort analysis, 39
cohort effect, 39
cohort study, 39
collaborative study, 40
collaborative trial, 40
cohort, 39
cohort analysis, 39
cohort effect, 39
cohort study, 39
collaborative study, 40
collaborative trial, 40
commercial institutional review board, 40
committee member, 40
community, 41
community trial, 41
comparison treatment, 41
competency requirement, 42
competitive range, 42
competitive renewal, 42
complete mask, 43
complete treatment crossover, 43
complete, completed, completing, completes, 42
completed trial, complete trial, 44
completely, 44
completely confounded, 44
completely masked, 44
complex trial, 44
compliance, 44
concurrent, 45
conditional life expectancy, 46
confound, 47
confounding variable, 48
consent, 48
consent, consented, consenting, consented, 48
contract, 53
contract office, 53
contract officer, 54
control treatment, 54
control-assigned, 54
control-assigned group, 54
control-assigned patient, 54
control-treated, 55
control-treated group, 55
control-treated patient, 55
controlled, 55
controlled clinical trial, 55
controlled trial, 56
cooperative, 56
correlation, 57
correlation coefficient, 57
cross-sectional analysis, 59
 crude, 60
currency term, 61
data, 63
data and safety monitoring, 63
data and safety monitoring committee (DSMC), 63
data collection site, 64
data coordinating center (DCC), 64
data dredging, 64
data edit, 64
data generation site, 65
data monitoring committee (DMC), 65
data sharing, 66
data simple trial, 66
dataset, 67
day, 67
def-identification, 68
deferral, 68
definitive, 68
definitive trial, 68
demonstration trial, 69
design variable, 70
dirty data, 72
disclosure, 72
diurnal, 74
dosage, 74
drop-in, 75
dropout, 75
dropout compensation, 76
dropout replacement, 76
drug, 76
drug lag, 77
drug reaction, 77
dummy table, 78
duplication, 78
early, 79
effectiveness, 80
effectiveness trial, 80
efficacy, 80
efficacy look, 81
efficacy monitoring, 81
efficacy review, 81
efficacy trial, 81
equipment, 82
endpoint, 83
enrollment, 83
enrollment goal, 84
enrollment override, 84
enrollment quota, 84
epidemiology, 84
 equipoise, 85
error, 85
ethical drug firm, 86
ethicist, 86
ethics review board (ERB), 86
ethnic origin, 86
evaluable study patient, 86
evaluable study patients, 86
ex-officio, 87
examination, 87
executive committee (EC), 87
executive session, 87
usage note (Continued)

exempt research, 87
experiment, 88
experimental drug, 89
experimental error, 89
experimental trial, 89
exploratory trial, 90
exploratory data analysis, 90
external study validity, 91
FDA Form 1572: Statement of investigator, 94
final, 97
final treatment result, 97
finder's fee, 97
fixed sample size, 98
fixed study design, 98
followup study, 100
fraud, 102
frequency, 102
frequentist analysis, 103
frozen state of equipoise, 103
funding period, 104
gender bias, 107
generalizability, 107
generalization, 107
grant, 109
group data, 110
group sequential design, 111
grouped data, 111
guideline, 111
guinea pig, 111
halo effect, 113
handbook, 113
haphazard, 113
haphazardization, 113
harm, 113
human subject, 117
identification, 119
identified data, 119
implied consent, 120
incentive, 121
incentive payment, 121
incompetent, 122
independent, 123
informed, 126
informed consent, 126
insider, 127
insider trading, 127
instrument, 128
intention to treat, 129
interacting variable, 129
interaction, 129
interim data analysis, 130
interim treatment result, 130
internal study validity, 131
intervention, 132
intervention trial, 132
interventionist, 132
investigator, 134
investigator IND, 134
investigator-initiated research proposal, 135
involve, involved, involving, involves, 135
justice, 137
lay, 142
lay committee member, 142
lay representative, 233
lead-in period, 142
left censored observation, 143
life expectancy, 144
linkable data, 146
long, 148
longitudinal, 148
look, 148
losses to followup, 148
lost to followup, 148
lottery, 149
mask, 151, 152
masked randomization, 152
masked treatment assignment, 152
masking level, 153
match, matched, matching, matches, 153
matching placebo, 153
missed contact, 157
missed visit, 157
monitor, monitored, monitoring, monitors, 159
month, 159
multi-study, 160
multi-study structure, 160
multi-trial structure, 160
multicenter, 161
multicenter study, 161
multicenter trial, 161
multidisciplinary trial, 161
multiple comparisons, 161
multiple looks, 162
multiple principal investigators, 163
natural trial, 166
negative, 166
negative control, 167
negative data, 167
negative effect, 167
negative result, 167
negative study, 167
negative treatment effect, 167
new drug, 168
New Drug Application (NDA), 168
nil, 168
nil treatment effect, 169
noncompetitive renewal, 169
nonhealth professional, 170
nonmasked treatment assignment, 171
nonmasked trial, 171
nonparametric, 171
nonrandom, 171
nonrandomized, 171
nonrandomized trial, 171
Index 353

objectivity requirement, 175
odd-even method of treatment assignment, 176
odds ratio, 177
off-protocol, 177
off-study, 177
on-protocol, 178
on-study, 179
on-treatment, 179
open, 179
open label, 179
open label trial, 180
open treatment assignment, 180
open trial, 180
optimum, 181
oral, 181
outcome, 182
outcome reporting bias, 182
outcome research, 182
overmatch, 183
overparameterize, 183
overstudy, overstudied, overstudying, 183
overview, 183
p-value, 185
parameter, 186
partially confounded, 187
patient advocate, 188
patient-centered outcomes research, 190
PC-based data entry, 190
performance monitoring, 191
performance review, 192
phase IV drug trial, 194
phase of trial, 194
placebo, 195, 196
placebo effect, 196
placebo patient, 196
placebo treatment, 197
placebo treatment effect, 197
placebo-assigned, 197
placebo-assigned group, 197
placebo-assigned patient, 197
placebo-control treatment, 197
placebo-controlled trial, 197
placebo-treated, 197
placebo-treated group, 198
placebo-treated patient, 198
plagiarism, 198
population-based trial, 200
positive data, 200
post-, 201
post-marketing surveillance, 201
post-stratify, 201
post-treatment followup, 201
potential bias, 202
potential conflict of interest, 202
pragmatic trial, 202
pre-, 202
preclinical, 203
prejudice, 204
prerandomization examination, 204
presentation, 204
preventative effect, 205
primary endpoint, 206
primary outcome, 206
primary outcome measure, 206
principal investigator (PI), 208
program, 210
project, 210
prospective, 211
protective effect, 211
protocol, 211
protocol amendment, 211
protocol deviation, 212
protocol override, 212
protocol suspension, 213
pseudorandom, 213
public repository, 213
publication, 214
publication bias, 214
publish, published, publishing, publishes, 214
quality assurance, 217
quality control center, 217
quality of life, 217
quality of life indicator, 218
quasirandom, 218
quasirandom number, 218
quota requirement, 219
quota sample, 219
quotification, 219
race, 221
random, 221
random assignment, 221
random error, 221
random sample, 222
randomization, 222
randomization breakdown, 223
randomization override, 223
randomized control trial (RCT), 223
randomized controlled trial (RCT), 224
randomized trial, 224
randomness, 224
randomness test, 225
rate, 225
ratio, 225
record audit, 227
record auditor, 227
record monitor, 228
record monitoring, 228
registration, 229
regression to the mean, 230
regular followup visit, 230
repeated measures design, 231
replication, 231
reportable event, 232
reported event, 233
repository, 233
representation, 233
usage note (Continued)
    representation bias, 233
    representative sample, 234
    representativeness, 234
    request for application (RFA), 234
    request for proposal (RFP), 234
    rescue medicine, 235
    rescue study, 235
    rescue treatment, 235
    research, 235
    research misconduct, 236
    research subject, 236
    resource center, 236
    retrospective, 237
    retrospective follow study, 237
    retrospective followup, 237
    retrospective study, 238
    reverse study site visit, 238
    reward, 238
    risk factor, 239
    run-in period, 240
    safety monitoring, 241
    safety review, 242
    salvage study, 242
    scheduled followup visit, 243
    scientific, 244
    scientific method, 244
    scientific misconduct, 244
    secular trend, 246
    selection bias, 246
    semi-, 247
    semiannual, 247
    semimonthly, 247
    semweekly, 247
    sequential data analysis, 247
    sequential sample size design, 248
    sequential trial, 248
    severed linkage, 249
    sex, 249
    sham, 249
    short, 250
    side effect, 250
    significant other, 251
    simple, 251
    simple trial, 251
    single-center, 252
    single-center trial, 252
    single-mask, 253
    small business, 254
    source document, 254
    sponsor-initiated research proposal, 255
    stage of trial, 256
    standard care, 256
    standard treatment, 257
    start-up patient, 258
    statistical association, 258
    statistical interaction, 258
    steering committee (SC), 258
    stopped trial, 260
    stopping guideline, 260
    stopping rule, 260
    stratification, 260
    stratified randomization, 261
    stratified-blocked randomization, 261
    stratify, 262
    study, 262
    study center, 262
    study group, 264
    study handbook, 264
    study investigator, 264
    study manual of operations, 264
    study participant, 264
    study patient, 264
    study principal investigator, 265
    study protocol, 265
    study review visit, 265
    study treatment, 266
    subcontract, 266
    subcontractor, 267
    subgroup analysis, 267
    subject, 268
    substudy, 268
    support center, 268
    surrogate outcome, 269
    survival rate, 269
    symmetrical treatment effects monitoring, 270
    systematic error, 270
    test for randomness, 274
    test patient, 275
    test run, 275
    test treatment, 275
    test-assigned, 275
    test-treated, 276
    test-treated group, 276
    test-treated patient, 276
    therapeutic placebo, 276
    time measure, 276
    time of enrollment, 277
    treater mask, 279
    treatment, 279
    treatment adherence, 279
    treatment arm, 279
    treatment compliance, 281
    treatment crossover, 281
    treatment effects monitoring, 282
    treatment effects monitoring committee (TEMC), 282
    treatment failure, 283
    treatment protocol suspension, 285
    treatment side effect, 285
    treatment-related feedback bias, 286
    trial, 287
    trial completer, 288
    trial stop, 288
    triple mask, 288
    triple-mask, triple-masked, 288
triple-masked trial, 288
unbalanced, 291
uncontrolled, 292
uncontrolled clinical trial, 292
uncontrolled trial, 292
undermatch, undermatched, undermatching, undermatches, 293
underrepresent, underrepresented, underrepresents, 293
understudy, understudied, understudying, understudies, 293
unique, 294
unmasked treatment assignment, 295
usual care, 296
vacuous term, 297
valid analysis, 297
validate, validated, validating, validates, 298
validation, 298
validity, 298
value laden term, 298
vanguard patients, 299
verbal, 299
verbal assent, 300
verbal consent, 300
vulnerable person, 300
weasel term, 301
week, 301
weekday, 301
well-controlled, 302
withdrawal, 302
workweek, 303

validity
construct validity, 52
content validity, 53
external study validity, 91
generalizability, 107
internal study validity, 131
measurement validity, 154
study validity, 266
test validity, 275
valid analysis, 297
validity, 298

Varco RL, 76

variable
adjustment variable, 4
baseline subgrouping variable, 17
baseline variable, 17
Bernoulli random variable, 19
dichotomous variable, 22
categorical variable, 28
censoring variable, 29
concomitant variable, 45
covariate, 58
dependent random variable, 69
dependent variable, 69
design variable, 70
dummy variable, 71
experimental variable, 89
explanatory variable, 90
extraneous variable, 91
followup variable, 100
independent random variable, 123
independent variable, 124
indicator variable, 124
interacting variable, 129
intermediate variable, 131
intervening variable, 132
lognormal random variable, 148
metric variable, 156
moderator variable, 158
normal random variable, 172
observation variable, 175
outcome variable, 183
primary outcome variable, 207
proxy variable, 213
random variable, 222
regression variable, 230
regressor, 230
standardized random variable, 257
stochastic variable, 259
statification variable, 261
subgrouping variable, 268
surrogate outcome variable, 269
treatment compliance variable, 281
treatment variable, 286
uncontrolled variable, 292
variable, 299

variance
analysis of variance (ANOVA), 8
covariance, 58
error variance, 85
homogeneity of variance, 116
residual variance, 236
sample variance, 242	
variation
coefficient of variation (CV), 38
extraneous source of variation, 91
interobserver variation, 132
intraobserver variation, 133
observer variation, 176
random variation, 222
sampling variation, 243
source of variation, 254
variation measure, 299
visit
  baseline visit, 17
  close-out followup visit, 36
  followup data collection visit, 100
  followup visit, 100
  followup visit schedule, 100
  ideal visit schedule, 119
  interim followup visit, 130
  missed contact, 157
  missed visit, 157
  post-close-out followup visit, 201
  post-trial followup visit, 202
  preassignment visit, 203
  pretreatment visit, 205
  regular followup visit, 230
  required followup visit, 235
  reverse study site visit, 238
  scheduled followup visit, 243
  screening visit, 245
  site visit, 253
  study home visit, 264
  study review visit, 265
  study site visit, 265
  study visit, 266
  transition study visit, 278
  treatment application and adjustment followup visit, 279
  treatment initiation visit, 284
  unscheduled followup visit, 296
  visit schedule, 300
  washout study visit, 301
  Vozeh S, 114
  Ware JH, 111
  Warner S, 224
  Weber FJ, 76
  Wei LJ, 296
  Wetherill GB, 296
  Whitney DR, 151, 302
  Wilcox AJ, 79
  Wilcoxon F, 151, 302
  Winau R, 113
  Winsor CP, 302
  Wittes J, 142, 196, 269
  World Health Organization (WHO), 303
  Wright S, 188
  X, Y, and Z, 305
  Yates F, 305
  Yellin AE, 76
  Zelen M, 198, 201, 288